

## CURRICULUM VITAE

**NAME:** Sheng-Nan Lu MD, MPH, PhD 盧勝男

**SEX:** Male

**CITIZENSHIP:** Taiwan, R.O.C.



**OFFICE ADDRESS & TEL. NO:**

(1) No. 6, Sec. West, Jiapu Rd., Puzih-City, Chiayi County, Taiwan.

(2) No. 123, 123 Ta Pei Road, Niao Sung Dist. 833, Kaohsiung City, Taiwan.

**EDUCATION:** (Oct 1977 ~ Jun 1984)

School of Medicine, Kaohsiung Medical College, Kaohsiung, Taiwan, R.O.C.

**POST-GRADUATE EDUCATION:**

- Master of Public Health (Sep 1984 ~ Jun 1986)  
Graduate Institute of Public Health College of Medicine,  
National Taiwan University, Taipei, Taiwan, R.O.C.
- Doctor of Medical Science (Ph.D) (Sep 1986 ~ Jan 1992);  
Graduate Institute of Medicine, Kaohsiung Medical College, Kaohsiung, Taiwan, R.O.C.

**ACADEMIC APPOINTMENT:**

- Lecturer of Internal Medicine, (Aug 1990 ~ Jul 1996); Department of Medicine, Kaohsiung Medical College, Kaohsiung City, Taiwan
- Associate Professor, School of Medicine (part time: Mar 2000~Jul 2003)(Full time: Aug 2003~Nov 2008), Chang Gung University College of Medicine, Kweishan, Taoyuan, Taiwan
- Professor, School of Medicine and Graduate Institute of Medical Sciences (Full time: Aug 2008 ~ July 2017), Chang Gung University College of Medicine, Kweishan, Taoyuan, Taiwan.
- Professor, School of Medicine (part time: Aug 2017 ~ present), Chang Gung University College of Medicine, Kweishan, Taoyuan, Taiwan.

**EMPLOYMENT RECORD:**

- Resident (Sep 1986 ~ Jul 1989) and Chief Resident (Aug 1989 ~ Jul 1990)  
Department of Internal Medicine, Kaohsiung Medical College Hospital, Kaohsiung, Taiwan.
- Visiting Staff (Aug 1990 ~ Jul 1996) of Hepatobiliary Division  
Department of Internal Medicine, Kaohsiung Medical College Hospital, Kaohsiung, Taiwan.
- Visiting Staff (Aug 1990 ~ Jul 1991, Aug 1994 ~ Jul 1996), Department of Occupational Medicine, Kaohsiung Medical College Hospital, Kaohsiung, Taiwan.

- Director of Hepatobiliary Division (Aug 1996 ~ Jul 1997), Department of Internal Medicine, God's Help Hospital, Chiayi, Taiwan
- Clinical associate professor of Hepato-Gastroenterology (Aug 1997~July 2007), Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
- Director of Gastroenterology Division (Apr 1999~ Jun 2002), Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
- Director of Occupational Medicine Department (Dec 2004~June 2012), Department of Occupational Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
- Director of Department of Internal Medicine (Jan 2008~ Jun 2008), Xiamen Chang Gung Hospital, Xiamen, Fujian, China.
- Clinical Professor of Division of Hepato-Gastroenterology (July 2007~June 2017), Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
- Vice-Chief of Internal Medicine (July 2016 – Jun 2017), Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
- Clinical Professor of Division of Hepato-Gastroenterology (July 2017~present), Department of Internal Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan.
- Vice Superintendent (July 2017 – present), Chang Gung Memorial Hospital, Chiayi, Taiwan.

#### **BOARD CERTIFICATION:**

- Specialist of Internal Medicine, R.O.C.
- Specialist of Gastroenterologist
- Specialist of Ultrasonography
- Specialist of Digestive Endoscopy
- Specialist of Occupational Medicine

**LICENSURES:** Chinese License No: 12725

#### **PROFESSIONAL AFFILIATIONS:**

Taiwan Society of Internal Medicine  
 The Gastroenterological Society of Taiwan (GEST)  
 The Digestive Endoscopy Society of Taiwan (DEST)  
 Taiwan Association for the Study of the Liver (TASL)  
 The Society of Ultrasound in Medicine, ROC. (SUMROC)  
 The National Public Health Association, ROC  
 The Environmental and Occupational Medicine Association, ROC  
 Taiwan Academy of Tumor Ablation (TATA)  
 President of the Taiwan Academy of Tumor Ablation (TATA)  
 Supervisor of the Gastroenterology Society of Taiwan (GEST)

Supervisor of the Taiwan Liver Cancer Association (TLCA)  
Committee for Liver Cancer and Hepatitis Prevention and Control, Minister of Health and Welfare,  
Taiwan.

### **Editorial Board:**

Journal of Gastroenterology and Hepatology (Editorial Board)  
PLoS One (academic editor)

### **RESEARCH INTEREST:**

- Internal Medicine, Gastroenterology, Hepatology, Interventional ultrasonography
- Epidemiology, Preventive Medicine, Community Medicine,

### **Clinical Trial:**

#### **(Principle Investigator)**

- XMRPG850031 ( IRB NO.94-1094C 原 94-145A1) 2006.03.01 ~ 2006.12.31  
A Phase 1/2 Open-Label Study to Evaluate Safety and Preliminary Evidence of Effectiveness of Tumor Ablation with Talaporfin Sodium (LS11) and Interstitial Light Emitting Diodes (LED) in the Treatment of Patients with Inoperable Hepatocellular Carcinoma (HCC).
- XMRP225 (IRB NO. 92-122) 2003.01.01 ~ 2006.12.31  
Double-Blind, Placebo-controlled, Randomized Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma with Poor Liver Reserve.
- XMRPG860161 (IRB NO.96-0400C) 2007.06.10 ~ 2008.06.09  
Phase II testing of ADI-PEG 20 in subjects with Unresectable Hepatocellular Carcinoma. ADI-PEG 20 用於治療手術無法切除之肝細胞癌患者之第二期臨床試驗
- XMRPG870131-2 ( IRB NO.97-0132A1 (95-0056A1) ) 2008.06.10 ~ 2010.12.04  
A Extension Study to Investigate the overall Survival of Subjects Receiving ADI-PEG 20. 調查接受 ADI-PEG 20 治療患者整體存活期的延伸試驗
- XMRPG890491-4 (IRB NO.99-0595A ) 2010.09.15 ~ 2013.12.31  
A phase IV, single-arm, open-label study of sorafenib (Nexavar®) in advanced hepatocellular carcinoma (HCC).
- XMRPG8A0451-3 (IRB NO. 100-0245A ) 2011.8.20 ~ 2015.12.31  
A multicenter, open label, phase I/randomized phase II study to evaluate safety, pharmacokinetics and efficacy of BIBF 1120 in comparison with sorafenib for advanced hepatocellular carcinoma patients in Asia. 多中心、開放標示、第一期? 隨機分組第二期試驗: 比較亞洲晚期肝癌患者, BIBF 1120 與 sorafenib 的安全性、藥物動力學性質與療效
- XMRPG8B0021-4 (IRB NO.100-3119A1) 2012.01.15 ~ 2015.09.30  
Randomized, Double-Blind, Multi-Center Phase III Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC)

Who Have Failed Prior Systemic Therapy.

- XMRPG8A0392 (IRB NO.99-3617A3) 2011.08.01 ~ 2018.12.31  
A phase II randomized, double-blinded, multicenter Asian study investigating the combination of transcatheter arterial chemoembolization (TACE) and oral everolimus (RAD001, Afinitor®) in localised unresectable hepatocellular carcinoma (HCC) – The TRACER Study)
- XMRPG8C0031-2 (IRB NO.101-3108A) 2013.01.03 ~ 2015.01.02  
A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combination with Ribavirin, in the Treatment of Naïve Genotype 2 and 3 Chronic Hepatitis C Subjects
- XMRPG8C0611-4 (IRB NO. 101-5306A) 2013.08.26 ~2017.04.17  
A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib.  
有關 Regorafenib 用於接受過蕾莎瓦(Sorafenib) 治療的肝細胞癌 (HCC) 病患的一項隨機、雙盲、安慰劑對照、多中心的第三期研究
- XMRPG8C0461-2 (IRB NO. 101-3535A) 2013.05.21 ~ 2015.04.20  
一項針對亞洲第 1 型基因型之慢性 C 型肝炎病毒感染受試者的第 1b 期，隨機分配、雙盲...
- XMRPG8D0131-2 (IRB NO. 102-2599A) 2014.03.20 ~ 2015.12.31  
一項以 refametinib(BAY 86-9766)用於具 RAS 突變之肝細胞癌(HCC)病患的前瞻性、單組、多中心、無對照、開放性、第 II 期試驗
- XMRPG8D0491-4 (IRB NO. 102-5961A) 2014.09.23 ~ 2018.09.30  
第三期、安慰劑對照、多國多中心、隨機分配、雙盲試驗，評估 K-333 (peretinoin) 用於亞洲肝癌完全治癒受試者之療效及安全性
- XMRPG8E0231-3 2015.06.03 ~ 2017.12.31  
評估 P1101 對於未接受干擾素治療之感染慢性 B 型肝炎病毒患者的抗病毒活性與安全性之開放性、隨機分配、有效藥對照、劑量探索的臨床 I / II 期試驗
- XMRPG8E0361-2 2015.07.28 ~ 2017.07.31  
一項第 IIB-III 期、開放性、隨機分配的比較試驗，針對亞太地區中罹患慢性 B 型肝炎的 HBeAg 陰性成人患者，評估停止核.(酸)類似物治療後， ABX203 維持 B 型肝炎疾病控制的療效
- XMRPG8E0511-3 2015.09.18 ~ 2018.02.28  
一項隨機分配、雙盲、安慰劑對照的試驗，用以評估 ABT- 450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) 以及 ABT-333 治療未曾接受 治療以及曾接受治療，患有非肝硬化、慢性 C 型肝炎病毒 (HCV) 基因亞型 1b 感染之亞洲...
- XMRPG8F0131-3 2016.03.08 ~ 2019.03.31  
一項針對未曾接受全身性治療的晚期肝細胞癌 (HCC) 患者，比較使用 Pexa-Vec(牛痘病毒顆粒球巨噬細胞群落刺激因子[GM-CSF]/胸?激?去活性病毒)後接受 Sorafenib 治療相較於 Sorafenib 治療的第三期、隨機分配...

- XMRPG8F0181-3 2016.04.08 ~ 2018.08.03  
對無法以手術切除肝細胞癌的受試者給予 MEDI4736 和 Tremelimumab 做為單一藥物治療和併用治療進行安全性、耐受性和臨床活性的試驗
- XMRPG8F0391-2 2016.06.16 ~ 2018/6/30  
利用 JKB-122 評估對於經干擾素(長效型或短效型)或干擾素和 Ribavirin 組合治療沒有反應的 C 型肝炎病毒陽性患者之肝臟功能 (丙胺酸轉胺?ALT 以及天門冬胺酸轉胺?AST)的第二期, 隨機、多劑量、雙盲、安慰劑控制的臨床試驗
- XMRPG8F0451~3 2016.08.01 ~ 2019.07.31  
一項隨機、多中心、第 III 期試驗, 以 Nivolumab 與 Sorafenib 對照做為晚期肝癌患者的第一線治療

**(Co-Principle Investigator )**

- A Randomized, Double-Blind Trial of LdT (Telbivudine) versus Lamivudine in Adults with Decompensated Chronic Hepatitis B and Evidence of Cirrhosis. ( 2004/05 ~ 2010/1)
- Studytitle: An open label, Comparative, Multi-Center Study, to evaluate efficacy and safety of peginterferon Alfa-2a plus ribavirin in the treatment of patients with chronic hepatitis C/hepatitis B co-infection and chronic hepatitis C. (2004/07~2006/12)
- Title of Study: An extension, observational protocol to evaluate the long term treatment effects of treatment with peginterferon alfa-2a plus ribavirin for patients with chronic hepatitis C/ hepatitis B co-Infection and chronic hepatitis C in the original study ML17862. (2006/01/01~present)
- Title of Study: A double blind, Randomized, Placebo-Control Multi-Center, Phase II Parallel Dose-Ranging Study to assess the Antifibrotic Activity of GI262570 in chronic Hepatitis C Subjects with Hepatic Fibrosis who Have Failed Prior Antiviral Therapy. (2006/06/08~2008/01/25)
- Satavaptan in the Prevention of Ascites Recurrence: a double-blind, randomized, parallel-group comparison of satavaptan at 5 to 10 mg daily versus placebo in the absence of diuretics in patients with recurrent ascites due to cirrhosis of the liver. ( 2006/10 ~ 2008/10)
- An open label study of adefovir dipivoxil for the treatment of patients with chronic hepatitis B (CHB) related advanced fibrosis or cirrhosis. (2006/08/01~2009/10/30)
- A Randomized, Double-Blind Study Evaluating Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B. ( 2007/04/20~2010/12/31 )
- Title of Study: A phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in combination with Ribavirin compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFN $\alpha$ 2a) in combination with Ribavirin in Interferon Alfa Naïve Subjects with Chronic Hepatitis C Genotype 2 or 3 ACHIEVE-2/3. Sponsor: Human Genomic Science (HGS). (2007/8/10~2008/9/9)
- Long term safety and tolerability of satavaptan in patients with cirrhosis of the liver that have been previously randomized and completed treatment in any of the phase III studies: EFC4492; EFC4493 or EFC6682: a double blind parallel group study comparing satavaptan at 5 to 10 mg daily versus

placebo. ( 2007/12 ~ present)

- Immunohistochemistry analysis of argininosuccinate synthetase expression in tissue samples from subjects with unresectable Hepatocellular Carcinoma. (2008/6/10~2009/6/9)
- A Multi-center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treated, Naïve Patients with HBeAg Positive Chronic Hepatitis due to Hepatitis B Virus. (2008/8/5~2009/11/30)
- A Multi-center Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treated, Naïve Patients with HBeAg Negative Chronic Hepatitis due to Hepatitis B Virus. (2008/8/5~2009/11/30)
- Randomized, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2b plus ribavirin) ENABLE 2 (Eltrombopag to Initiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C Related Liver Disease). (2008/6/10~ present )
- A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination with Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma. (2008/12/1~2011/1/31)
- Title of Study: An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albuterferon alfa-2b administered every 4 weeks plus ribavirin in interferon alfa-naïve patients with genotype 2/3 chronic hepatitis C. (2009/3/2 ~ present)
- Randomized, Observational Study of Entecavir to Assess Long-term Outcomes Associated with Nucleoside/Nucleotide Monotherapy for Patients with Chronic HBV Infection: The REALM Study. (2009/3 ~ 2016/3)
- A Randomized Controlled Trial to Evaluate the Therapeutic Effect of Telbivudine with or without Prednisolone Priming in Patients with Chronic Hepatitis B. (2008/9 ~ present)
- A Phase II Randomized, Controlled Study to Evaluate the Quality of Life, Survival and Therapeutic Benefits of MS-20 in Patient with Advanced Hepatocellular Carcinoma. (2009/11/1~2010/5/31 )
- Multicentre, Prospective Study of First-line Antibiotic Therapy for Early-stage Low-grade and High-grade Gastric Mucosa-associated Lymphoid Tissue-type Lymphoma and Potential Predicting Factor for Treatment Outcome. (2006/12/30~2009/12/30)
- A Randomization Trial of Adjuvant Lamivudine / Adefovir Dipivoxil Against Recurrence in Post-operative HBV-related Hepatocellular Carcinoma. (2008/8/31 ~ present)
- Phase 2, Randomized study of CS-1008 in combination with sorafenib compared to sorafenib alone as first-line systemic therapy in subjects with advanced hepatocellular carcinoma. (2009/12/1~2013/10/6)

## NSC (NMRP)

- NMRP261 (NSC 88-2314-B-182A-022-) 1998.08.01 ~ 2000.07.31  
C型肝炎盛行地區基因型及C型肝炎抗體陽性學童之流行病學研究
- NMRP600 (NSC 89-2315-B-182A-004-) 1999.08.01 ~ 2000.07.31  
D型肝炎盛行社區之流行病學研究
- NMRPG0010 (NSC 90-2314-B-182A-031-MH) 2001.08.01 ~ 2003.01.31  
重新審視並尋求新的急性C型肝炎替代診斷方式以還原被低估的南台灣急性C型肝炎的流行狀況
- NMRPG1174 (NSC 91-2314-B-182A-177) 2002.08.01 ~ 2003.07.31  
評估以血小板數界定C型肝炎相關肝癌高危險群的可行性-臨床、流行病學及實驗室的研究
- NMRPG2062 (NSC 92-2314-B-182A-046) 2003.08.01 ~ 2004.12.31  
黃麴毒素是否為台灣地區肝臟疾病之危險因子
- NMRPD3080 (NSC 93-2314-B-182-048) 2004.08.01 ~ 2005.07.31  
台灣南部急性C型肝炎之流行病學及臨床研究
- NMRPD140821 (NSC 93-2314-B-182-065) 2005.08.01 ~ 2006.07.31  
梓官鄉成年居民之肝病追蹤研究：(1)C型肝炎發生率與相關因子、(2)肝炎病患求醫行為與疾病預後的關係、(3)高盛行地區居民對肝炎的認知。
- NMRPD150091 (NSC 95-2314-B-182-018) 2006.08.01 ~ 2007.07.31  
全面接種B型肝炎疫苗後最初十年出生的世代中B型肝炎帶原者在青少年時的臨床與病毒表徵
- NMRPD160411-3 (NSC 96-2314-B-182-021-MY3) 2007/8/1 ~ 2010/7/31  
台南縣全縣成人兩個年度十萬人次肝癌篩檢之後續追蹤研究(1-3/3)
- NMRPD1B0351 (NSC 101-2314-B-182-018) 2012/8/1 ~ 2013/10/31  
建立胎兒蛋白用於篩檢肝癌的證據：社區及醫院內之長期追蹤研究
- NMRPD1C0251 (NSC 102-2314-B-182-022) 2013/8/1 ~ 2014/7/31  
肝癌病人的肝外原發性癌資料庫之建立：1.探討臨床表徵與預後； 2.用病例對照研究法探討發生率高的六種癌之危險因子
- NMRPD1D0481 (NSC 103-2314-B-182-017) 2014.08.01 ~ 2015.07.31  
以台南民國92年至102年之社區複合式篩檢資料及存留生物檢體進行肝病流行病學研究及防治的成效評估
- NMRPD1E0401 (NSC 104-2314-B-182-014) 2015.08.01 ~ 2016.07.31  
以台南民國92年至102年之社區複合式篩檢資料及存留生物檢體進行肝病流行病學研究及防治的成效評估(後續計劃)
- NMRPD1F0131(MOST 105-2314-B-182-021-MY2) 2016.08.01 ~ 2017.07.31  
肝病社區防治的長期效果(1/2)
- NMRPG6F6022(MOST 105-2314-B-182A-147-MY2)2017.08.01 ~ 2018.07.31  
肝病社區防治的長期效果(2/2)

- NMRPG6H0011 (MOST 107-2314-B-182A-111) 2018.08.01 ~ 2019.07.31  
前瞻建立雲嘉南地區公共衛生及慈善BC型肝炎篩檢資料庫，以長短期評估篩檢效益

#### **DOH (PMRP)**

- NMRPG0038 (DOH90-HP-1001) 2001.08.01~2002.12.31  
台灣地區肝癌病毒性病因學之時代變遷與地理差異：多中心之回溯性整合研究
- PMRPG0040 (DOH90-TDB-03) 2001.08.01~2002.12.31  
台灣B型及C型肝炎慢性感染所引發之肝癌，其時間及地理變遷研究計劃之整合
- PMRPG2059 (DOH92-HP-2503) 2003.07.01~2004.12.31  
辨識台灣C型肝炎盛行地區:(一)肝炎病毒性病因學枝時代變遷與地理差異多中心之回溯性整合研究延續計劃，(二)由全民健保成人健檢肝機能異常率推估社區C型肝炎抗體陽性率
- PMRPG4017 (DOH94-DC-1041) 2005.01.01~2005.12.31  
疾病管制局-我國急性C型肝炎報資料可性度的再探討
- PMRPG6H0021 (D1070101) 2018.03.01~2018.12.10  
高盛行地區病毒性B、C型肝炎篩檢及介入服務模式評估計畫

#### **CGMH (CMRP)**

- CMRPG763 1998.02.01 ~ 1999.01.31  
以C及G型肝炎病毒標記做為血液相關傳染病流行病學的研究工具
- CMRPG935 2000.04.01 ~ 2001.03.31  
建立C型肝炎高盛行地區的長期追蹤社區調查與C型肝炎的分子流行病學研究(梓官鄉)
- CMRPG8032 2003.02.01 ~ 2006.01.31  
C型肝炎高盛行區以血小板低下做為選取肝癌高危險群的唯一血清標記
- CMRPG83053 2005.12.01 ~ 2006.01.31  
以高雄長庚醫院十五年來原發性肝細胞癌治療成績的存活分析為例來建立並推廣本院癌症存活分析之模式
- CMRPG850141 2006.05.01 ~ 2007.04.30  
非侵襲性肝纖維化測定-慢性C型肝炎引起肝纖維化之診斷追蹤預後及社區肝癌篩檢的應用
- CMRPG870101 2008.03.01 ~ 2009.02.28  
慢性C型肝炎個案經過治療後得到持續病毒反應後延遲復發之發生率及可能原因
- CMRPG870581-3 2008.08.01 ~ 2011.07.31  
建立高雄長庚醫院的成果研究分析：肝癌病患前瞻性和即時分析的成果研究
- CMRPG880741 2009.06.01 ~ 2010.08.31  
慢性C型肝炎病患經抗病毒治療達到完全病毒反應之C型肝炎抗體效價及血小板計數變化長期追蹤研究
- CMRPG880881-2 2009.07.01 ~ 2011.06.30



持續肝機能檢驗正常之慢性B型肝炎病患的分類及其自然病史

- CMRPG8B1411-3 2013.01.01 ~ 2016.07.31  
肝癌資料庫建立與分析之系列研究：著重於腫瘤治癒再復發個案及標靶藥物治療個案分析
- CMRPG8C1061 2014.08.01 ~ 2016.03.31  
(國)肝癌病人的肝外原發性癌:1. 探討臨床表徵與預後;2. 用病例對照研究法探討發生率高的六種癌之危險因子(第二、三年)
- CLRPG8F0101-2 2016.06.01 ~ 2018.05.31  
生物統計中心前趨計畫
- CMRPG8F0441-2 2016.08.01 ~ 2018.07.31  
以長時完整大量的本院肝癌資料庫在全國性議題扮演重要角色(1/3)
- CMRPG8F0851 2016.12.01 ~ 2018.11.30  
肝癌和肝外原發性癌: 1.探討其臨床表徵與預後; 2.肝癌合併大腸癌其危險因子與相關基因標記的探討

#### 基金會提供(SMRP)

- SMRPG890031-3 (IRB NO.99-1663B) 2010.09.01 ~ 2014.12.31  
Two community-based prevention and control programs for chronic viral hepatitis in counties with or without well-screening: (1) a comprehensive care program of patients with chronic hepatitis B and C detected by community screening in a rural township (2) identify HCV-endemic villages from an HBV-endemic county as candidates needed to be urgent intervention.

#### 著作:

##### 【學位論文】:

碩士學位論文：台灣地區原發性肝細胞癌之病例對照研究。

臺灣大學醫學院公共衛生研究所。民國七十五年六月。

博士學位論文：肝細胞癌盛行地區肝膽疾病之流行病學研究。

高雄醫學院醫學研究所。民國八十一年一月。

#### Publications: more than 360 papers

1. Chuang WL, Chang WY, **Lu SN**, Lin ZY, Chen SC, Hsieh MY, Wang LY, Wu CC, Chang SF, Chow TY. Hepatitis D virus infection in patients with chronic hepatitis B virus infection. Kaohsiung J Med Sci 1987; 3:121-127.
2. Hsieh MY, **Lu SN**, Chang WY, Wang LY, Chen SC, Chuang WL, Wu CC . An epidemiological study on hepatitis B virus infection in Kaohsiung Medical College freshmen. Kaohsiung J Med Sci 1987; 3:318-325. [in Chinese]
3. Wu CC, **Lu SN**, Ho YH. Normal upper limit of extrahepatic bile duct dimension by real-time ultrasonography: a reevaluation. Kaohsiung J Med Sci 1987; 3:18-622. [in Chinese]
4. **Lu SN**, Lin TM, Chen CJ, Chen JS, Liaw YF, Chang WY, Hsu ST. A case-control study of primary hepatocellular carcinoma in Taiwan. Cancer 1988; 62: 2051-2055, 1988.

5. Liu TY, **Lu SN**, Su WP, Chang WY, Wang LY, Hsieh MY, Chuang WL, Chen SC, Chen CJ. Prediction of fatty liver from serum triglyceride levels and body weight indexes. *Kaohsiung J Med Sci* 1990; 6:289-294.
6. **Lu SN**, Tseng SJ, Yang CH, Yen YI, Tsai JH, Chen CW. Time spent and satisfaction of new out-patients in Department of Internal Medicine Kaohsiung Medical College Hospital. *Kaohsiung J Med Sci* 1990; 6:490-500.
7. Wang LY, Chang WY, **Lu SN**, Chen TP. Sequential Change of serum transaminase and abdominal sonography in patients with suspected dengue fever. *Kaohsiung J Med Sci* 1990; 6: 483-489.
8. Chen SC, Lin ZY, **Lu SN**, Chuang WL, Hsieh MY, Wang LY, Tsai JF, Chang WY. The effect of Pitressin and Glypressin in variceal bleeding: a preliminary clinical trial. *Kaohsiung J Med Sci* 1990; 6: 551-555.
9. **Lu SN**, Chang WY, Wang LY, Hsieh MY, Chuang WL, Chen SC, Su WP, Tai TY, Wu MM, Chen CJ. Risk factors for gallstone among Chinese in Taiwan: a community sonographic survey. *J Clin Gastroenterol* 1990; 12: 542-546.
10. Hsieh MY, Wu DK, **Lu SN**, Wang LY, Chang WY. The outcome of hepatocellular carcinoma treated with transcatheter arterial chemo-embolization. *Kaohsiung J Med Sci* 1990; 6: 628-635.
11. **Lu SN**, Chen TP, Chung CL. Association between Dengue outbreak and weather in southern Taiwan. *J Natl Public Health Assoc* 1990; 10: 114-119. [ in Chinese]
12. **Lu SN**, Wang LY, Chang WY, Chen CJ, Su WP, Chen SC, Chuang WL, Hsieh MY. Abdominal sonographic screening in a single community. *Kaohsiung J Med Sci* 1990; 6: 643-646.
13. Chen SC, **Lu SN**, Lai CT, Jean JY, Hsiao CL, Hsu PT. Aqueous acupuncture for postoperative pain--a matched controlled trial. *Kaohsiung J Med Sci* 1991;7:466-70.
14. Chen CJ, Liang KY, Chang AS, Chang YC, **Lu SN**, Liaw YF, Chang WY, Sheen MC, Lin TM. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. *Hepatology* 1991; 13:398-406.
15. Yu MW, You SL, Chang AS, **Lu SN**, Liaw YF, Chen CJ. Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. *Cancer Research*. 1991; 51 :5621-5.
16. Chuang SF, **Lu SN**, Hwang ML, Cheng YR, Pan CY, Fang YS, Ko CC, Chang WY. Primary treatment of contaminated syringes and needles in a ward. *Kaohsiung J Med Sci* 1991; 7:542-4. [ in Chinese]
17. Lin TM, Chen CJ, **Lu SN**, Chang AS, Chang YC, Hsu ST, Liu JY, Liaw YF, Chang WY. Hepatitis B virus e antigen and primary hepatocellular carcinoma. *Anticancer Research* 1991; 11:2063-5.
18. **Lu SN**, Chen CJ. Prevalence of hepatitis B surface antigen carrier status among residents in the endemic area of chronic arsenicism in Taiwan. *Anticancer Res* 11: 229-234, 1991.
19. Wu MT, Huang HL, Liu HW, **Lu SN**, Huang CT, Hsu WC, Chau TT. The appointment system at the Department of Family Medicine of Kaohsiung Medical College. *Chinese J Family Med* 1991; 1: 45-52.
20. Chang WY, Wang LY, Chuang WL, Chen SC, **Lu SN**, You SL. Anti-HCV antibody in Chinese cirrhotic patients with or without hepatocellular carcinoma: Relationship to multitransfusion. *J Gastroenterol Hepatol* 1992; 7:128-31.
21. **Lu SN**, Chang WY, Chen CJ, You SL. Evaluation of serum alanine transaminase as a surrogate for hepatitis C virus screening. *J Clin Gastroenterol* 1992; 14:354-5. [letter]
22. Lin ZY, Chang WY, Wang LY, Su WP, **Lu SN**, Chen SC, Chuang WL, Hsieh MY, Tsai JF. Clinical utility of pulsed Doppler in the detection of arteriportal shunting in patients with hepatocellular carcinoma. *J Ultrasound Med* 1992; 11:269-73.
23. Chang WY, Chen CJ, **Lu SN**, You SL, Chuang WL, Chen SC, Su WP, Wang LY, Hsieh MY, Wu MM, Tai TY. Relationship between fatty liver, alanine aminotransferase, HBsAg and hepatitis C virus. *J Gastroenterol Hepatol* 1992; 7:455-8.
24. Hsieh MY, **Lu SN**, Wang LY, Liu TY, Su WP, Lin ZY, Chuang WL, Chen SC, Chang WY. Alpha-fetoprotein in patients with hepatocellular carcinoma after transcatheter arterial embolization. *J Gastroenterol Hepatol* 1992; 7:614-7.
25. Hsieh MY, Chang WY, Wang LY, Chen SC, Chuang WL, **Lu SN**, Wu DK. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization and analysis of prognostic factors. *Cancer Chemotherapy Pharmacol* 1992; 31 Suppl: S82-5.
26. Chen CJ, Zhang YJ, **Lu SN**, Santella RM. Aflatoxin B1 DNA adducts in smeared tumor tissue from patients with hepatocellular carcinoma. *Hepatology* 1992; 16:1150-5.
27. Chuang WL, Chang WY, **Lu SN**, Su WP, Lin ZY, Chen SC, Hsieh MY, Wang LY, You SL, Chen CJ. The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study. *Cancer* 1992; 69:2052-4.
28. Chuang WL, Chang WY, **Lu SN**, Lin ZY, Chen SC, Hsieh MY, Wang LY, You SL, Chen CJ. The role of hepatitis C virus in chronic hepatitis B virus infection. *Gastroenterol Jap* 1993; 28 Suppl 5:23-7.
29. Hsiao TM, Ho CK, Su WP, Hwang JJ, Tsai MS, Chau TT, **Lu SN**, Chang WY. Asbestos related pleural

- plaques in retired boiler room workers. *Kaohsiung J Med Sci* 1993; 9:74-9.
30. Chuang WL, Omata M, Ehata T, Yokosuka O, Ito Y, Imazeki F, **Lu SN**, Chang WY, Ohto M. Precore mutations and core clustering mutations in chronic hepatitis B virus infection. *Gastroenterology*. 1993; 104:263-71.
  31. Chen CJ, **Lu SN**, You SL, Wu MH, Wang LY, Lee LT, Huang GT, Yang PM, Lee HS, Lo CS, Chen CT, Ho SC, Lee CT, Lin CG, O YC. Community-based hepatocellular carcinoma screening in seven townships in Taiwan. *J Formos Med Assoc* 1995; 94: s94-102.
  32. Huang JF, Chen SC, **Lu SN**, Lin ZY, Chuang WL, Hsieh MY, Wang LY, Tsai JF, Chang WY, Chen CJ. Prevalence and size of simple hepatic cysts in Taiwan: community- and hospital-based sonographic surveys. *Kaohsiung J Med Sci* 1995; 11:564-7.
  33. Wang JH, Wang LY, Lin ZY, Chen SC, Kang SC, Chuang WL, **Lu SN**, Hsieh MY, Tsai JF, Chang WY. Doppler sonography of common hepatic duct tumor invasion in hepatocellular carcinoma: report of two cases. *J Ultrasound in Med* 1995; 14:471-4.
  34. Chen CJ, Wang LY, **Lu SN**, Wu MH, You SL, Zhang YJ, Wang LW, Santella RM. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. *Hepatology* 1996; 24:38-42.
  35. Hsieh MY, Chen SC, **Lu SN**, Wang LY, Tsai JF, Chuang WL, Lin ZY, Chang WY. Treatment of hepatocellular carcinoma smaller than 5cm by transcatheter arterial chemoembolization. *Kaohsiung J Med Sci* 1996; 12: 274-6.
  36. Lin ZY, Wang JH, Wang LY, **Lu SN**, Chen SC, Chuang WL, Hsieh MY, Tsai JF, Chang WY. Percutaneous intravascular ethanol injection of supplying tumor vessel in the treatment of hepatocellular carcinoma larger than 3 cm. *J Ultrasound Med* 1996; 15:155-160.
  37. Yu ML, Chuang WL, **Lu SN**, Chen SC, Wang JH, Lin ZY, Hsieh MY, Wang LY, Chang WY. The genotypes of hepatitis C virus in patients with chronic hepatitis C virus infection in southern Taiwan. *Kaohsiung J Med Sci* 1996; 12: 606-612.
  38. Sun CA, Farzadegan H, You SL, **Lu SN**, Wu MH, Wolfe L, Hardy W, Huang GT, Yang PM, Lee HS, Chen CJ. Mutual confounding and interactive effects between hepatitis C and hepatitis B viral infection in hepatocellular carcinogenesis: a population-based case-control study in Taiwan. *Cancer Epidem Biomar* 1996; 5: 173-178.
  39. Lin ZY, Wang JH, Wang LY, **Lu SN**, Chen SC, Chuang WL, Hsieh MY, Tsai JF, Chang WY. Changes of intrahepatic portal hemodynamics in an early stage hepatic abscesses. *J Ultrasound Med* 1996; 15: 595-598.
  40. Yu ML, Chuang WL, Chen SC, **Lu SN**, Wang JH, Lin ZY, Hsieh MY, Wang LY, Chang WY. Treatment of chronic hepatitis C with interferon-alpha: a preliminary report. *Kaohsiung J Med Sci* 1996; 12: 581-589.
  41. Yu ML, Chang WL, Chow TY, Chen SC, **Lu SN**, Lin ZY, Hsieh MY, Wang LY, Chang WY. The status of serum HBV DNA in HBsAg-positive hepatocellular carcinoma. *Kaohsiung J Med Sci* 1996; 12: 466-470.
  42. Su YC, Wang WM, Chen LT, Chiang W, Chen CY, **Lu SN**, Jan CM. High seroprevalence of IgG against *Helicobacter pylori* among endoscopists in Taiwan. *Digest Dis Sci* 1996; 8:1571-1576.
  43. Wang LY, Hatch M, Chen CJ, Levin B, You SL, **Lu SN**, Wu MH, Wu WP, Wang LW, Wang Q, Huang GT, Yang PM, Lee HS, Santella RM. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. *Int J Cancer* 1996; 67: 620-625.
  44. Chen CJ, Yen JH, Tsai WC, Lin MB, Hsu SH, Tsai JJ, Lin HC, **Lu SN**, Liu GC, Lin SF, Liu HW. Decrease bone mineral density in pre-menopausal patients with systemic lupus erythematosus *Kaohsiung J Med Sci* 1996; 12:567-572.
  45. Lin ZY, Wang LY, Wang JH, **Lu SN**, Chen SC, Chuang WL, Hsieh MY, Tsai JF, Chang WY. Clinical utility of color Doppler sonography in differentiation of hepatocellular carcinoma from metastases and hemangioma. *J Ultrasound Med* 1997; 16: 51-58.
  46. Wang LY, Wang JH, Lin ZY, Yu ML, **Lu SN**, Chuang WL, Chen SC, Hsieh MY, Tsai JF, Chang WY. Hepatic focal nodular hyperplasia: findings on color Doppler ultrasound. *Abdominal Image* 1997; 22:178-181.
  47. Liu JH, **Lu SN**, Ho CK, Wang JH, Chuang WL, Chang WY. Changes of hepatitis B markers among young adults in a hepatitis B virus endemic area: a follow up study on medical students. *Kaohsiung J Med Sci* 1997; 15: 286-292.
  48. **Lu SN**, Chue PY, Chen HC, Wu MH, Chen IL, Huang JF, Wang JH, Peng CF, Shih CH, You SL, Lu CF, Chen CJ, Chang WY. Different Viral Etiology of Hepatocellular Carcinoma between Two Hepatitis B and C Endemic Townships in Taiwan. *J Gastroenterol Hepatol* 1997; 12: 547-550.
  49. **Lu SN**, Chue PY, Chen IL, Wang JH, Huang JF, Peng CF, Shih CH, Chang WY. Incidence of hepatitis C endemic township in southern Taiwan. *Kaohsiung J Med Sci* 1997;13: 605-608.
  50. Wang JH, **Lu SN**. Use of color ultrasound in percutaneous intravascular ethanol injection of supplying tumor vessel of hepatocellular carcinoma- a case report. *J Med Ultrasound* 1998; 6: 48-51.

51. **Lu SN**. Go through hepatitis C endemic township. *Chinese J Publ Health (Taipei)* 1998; 17: 175-181. [Editorial] [in Chinese]
52. Huang YH, Wu JC, **Lu SN**, Chiang TY, Chang FY, Lee SD. Polygenetic analysis to document a common source of hepatitis D virus infection in a mother and her child. *Chinese Med J (Taipei)* 1999; 62: 28-32.
53. Wang JH, **Lu SN\***, Wu JC, Huang JF, Yu ML, Chen SC, Chuang WL. A hyperendemic community of hepatitis B virus and hepatitis C virus infection in Taiwan. *Trans Royal Soc Tropic Med Hyg* 1999; 93: 253-254. [short report]
54. Chen IL, **Lu SN\***, Wu CL. Anti-HCV prevalence among villages in an endemic township: a community study in Tzukuang, Kaohsiung. *Chinese J Publ Health (Taipei)* 1999;18:313-318. [in Chinese]
55. Dai CY, Yu ML, Chuang WL, **Lu SN**, Wang JH, Huang JF, Hou C, Chen SC, Lin ZY, Hsieh MY, Wang LY, Tsai JF, Chang WY. The epidemiology of TT virus (TTV) infection in a hepatitis C and B virus hyperendemic area of southern Taiwan. *Kaohsiung J Med Sci* 2000; 16: 500-509.
56. **Lu SN**, Chen HC, Tang CM, Wu MH, Yu ML, Chuang WL, Lu CF, Chang WY, Chen CJ. Prevalence and manifestations of hepatitis C seropositivity in children in an endemic area. *Pediatr Infect Dis J.* 1998 Feb;17(2):142-5.
57. Wang JH, **Lu SN\***, Hsu CT. Hepatitis C is one major viral etiology of hepatocellular carcinoma in Chiayi and Yingling. *J Int Med Taiwan* 1998 Sep; 9(3): 120-125 [in Chinese]
58. **Lu SN**, Ho CK, Yu ML, Wang JH, Chuang WL. Detection and treatment of acute hepatitis C by needlestick among medical personnel. *Gastroenterol J Taiwan* 1998 Jun; 15 (2): 134-137.
59. Tsai YY, **Lu SN**, Changchien CS, Lee CM, Wang JH, Eng HL, Chang WC. Ultrasound-guided 22-gauge fine needle aspiration cytology in diagnosis of liver tumors. *J Int Med Taiwan* 1999 Jun; 10(3): 108~112.
60. Lee CM, **Lu SN**, Changchien CS, Yeh CT, Hsu TT, Tang JH, Wang JH, Lin DY, Chen CL, Chen WJ. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. *Cancer.* 1999 Oct 1;86(7):1143-50.
61. Su YC, **Lu SN**, Wu DC, Chen LT, Wang WM, Wu DK, Chen CY, Jan CM. Severe gastric mucosa injury after percutaneous pure ethanol injection therapy for hepatocellular carcinoma. *Gastrointest Endosc.* 2000 Mar;51(3):350-3.
62. **Lu SN\***, Lee CM, Changchien CS, Chen CJ. Excess mortality from hepatocellular carcinoma in an HCV-endemic township of an HBV-endemic country (Taiwan). *Trans R Soc Trop Med Hyg.* 1999 Nov-Dec;93(6):600-2.
63. **Lu SN\***, Liu JH, Wang JH, Lu CC. Secular trends of HBeAg prevalence among HBsAg-positive delivery mothers in a hepatitis B endemic area. *J Trop Pediatr.* 2000 Apr;46(2):121-3.
64. Leung SW, Huang EY, Cheng YF, **Lu SN**. Conformal radiation therapy for hepatoma with portal vein thrombosis. *Br J Radiol.* 2000 May;73(869):550-2. [case report]
65. Huang WS, Changchien CS, **Lu SN**. Adult intussusception: a 12-year experience, with emphasis on etiology and analysis of risk factors. *Chan Gung Med J.* 2000 May;23(5):284-90.
66. Su YC, Wang WM, Wang SY, **Lu SN**, Chen LT, Wu DC, Chen CY, Jan CM, Horowitz M. The association between *Helicobacter pylori* infection and functional dyspepsia in patients with irritable bowel syndrome. *Am J Gastroenterol.* 2000 Aug;95(8):1900-5.
67. Yu ML, Chuang WL, Dai CY, **Lu SN**, Wang JH, Huang JF, Chen SC, Lin ZY, Hsieh MY, Tsai JF, Wang LY, Chang WY. The serological and molecular epidemiology of GB virus C/hepatitis G virus infection in a hepatitis C and B endemic area. *J Infect.* 2001 Jan;42(1):61-6.
68. Wang JH, **Lu SN\***, Changchien CS, Lee CM, Tung HD, Chen TM. Flash echo gray scale imaging with subtraction in assessment of small hepatocellular carcinoma treated with percutaneous ethanol injection: preliminary report. *J Ultrasound Med.* 2001 May;20(5):539-44.
69. Sun CA, Wang LY, Chen CJ, **Lu SN**, You SL, Wang LW, Wang Q, Wu DM, Santella RM. Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan. *Carcinogenesis.* 2001 Aug;22(8):1289-94.
70. Hung CH, Changchien CS, **Lu SN**, Eng HL, Wang JH, Lee CM, Hsu CC, Tung HD. Sonographic features of hepatic adenomas with pathologic correlation. *Abdom Imaging.* 2001 Sep-Oct;26(5):500-6.
71. Sun CA, Chen HC, **Lu SN**, Chen CJ, Lu CF, You SL, Lin SH. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors. *J Med Virol.* 2001 Sep;65(1):30-4.
72. Yu ML, Chuang WL, Chen SC, Dai CY, Hou C, Wang JH, **Lu SN**, Huang JF, Lin ZY, Hsieh MY, Tsai JF, Wang LY, Chang WY. Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. *J Med Virol.* 2001 Sep;65(1):58-65.
73. Hsu CC, Chen JJ, Hu TH, **Lu SN**, Changchien CS. Famotidine versus omeprazole, in combination with

- amoxicillin and tinidazole, for eradication of *Helicobacter pylori* infection. *Eur J Gastroenterol Hepatol*. 2001 Aug;13(8): 921-6.
74. Liu YW, Chou FF, Sheen-Chen SM, **Lu SN**, Chiu KW, Chuah SK, Chen WJ, Eng HL. Gallbladder cancer: a review of 39 cases. *Formosan J Surg* 2001 Jan; 34(1): 16-21.
  75. Hu TH, Tsai TL, Hsu CC, **Lu SN**, Hsiao M, Changchien CS. Clinical characteristics of double pylorus. *Gastrointest Endosc*. 2001 Oct;54(4):464-70.
  76. Huang JF, **Lu SN\***, Chue PY, Lee CM, Yu ML, Chuang WL, Wang JH, Dai CY, Chen IL, Shih CH, Chang WY. Hepatitis C virus infection among teenagers in an endemic township in Taiwan: epidemiological and clinical follow-up studies. *Epidemiol Infect*. 2001 Dec;127(3):485-92.
  77. Liao CA, Lee CM, Wu HC, Wang MC, **Lu SN**, Eng HL. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. *Br J Haematol*. 2002Jan;116(1):166-9.
  78. Chen TH, Chen CJ, Yen MF, **Lu SN**, Sun CA, Huang GT, Yang PM, Lee HS, Duffy SW. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. *Int J Cancer*. 2002 Mar 10;98(2):257-61.
  79. Chen CH, Changchien CS, **Lu SN**, Wang JH, Hung CH, Lee CM. Lamivudine treatment for recurrent pancreatitis associated with reactivation of chronic B hepatitis. *Dig Dis Sci*. 2002 Mar;47(3):564-7.
  80. Wang JH, **Lu SN**, Lee CM, Lee JF, Chou YP. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. *Scand J Gastroenterol*. 2002 Mar;37(3):366-9.
  81. Ong GY, Hsu CC, Changchien CS, **Lu SN**, Huang SC. Eosinophilic gastroenteritis involving the distal small intestine and proximal colon. *Chang Gung Med J*. 2002 Jan;25(1):56-61.
  82. Huang JF, Wang LY, Lin ZY, Chen SC, Hsieh MY, Chuang WL, Yu MY, **Lu SN**, Wang JH, Yeung KW, Chang WY. Incidence and clinical outcome of icteric type hepatocellular carcinoma. *J Gastroenterol Hepatol*. 2002 Feb;17(2): 190-5.
  83. Tsai YY, **Lu SN**, Changchien CS, Wang JH, Lee CM, Eng HL, Chang WC. Combined cytologic and histologic diagnosis of liver tumors via one-shot aspiration. *Hepatogastroenterology*. 2002 May-Jun;49(45):644-7.
  84. Tung HD, **Lu SN\***, Lee CM, Wang JH, Chen TM, Hung CH, Huang WS, Changchien CS. Antiviral treatment responses in patients with chronic hepatitis C virus infection evaluated by a third generation anti-hepatitis C virus assay. *J Viral Hepat*. 2002 Jul;9(4):304-8.
  85. Wang JH, Chen TM, Tung HD, Lee CM, Changchien CS, **Lu SN\***. Color Doppler sonography of bile duct tumor thrombi in hepatocellular carcinoma. *J Ultrasound Med*. 2002 Jul;21(7):767-72
  86. Chen TM, **Lu SN**, Wang JH, Hung CH, Tung HD. Relationship between flash echo gray scale imaging features and pathologic findings in hepatic adenoma. *J Ultrasound Med*. 2002 Jul;21(7):821-4.
  87. Yang HI, **Lu SN**, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ. Hepatitis B e antigen and the risk of hepatocellular carcinoma. *N Engl J Med*. 2002 Jul 18;347(3):168-74.
  88. Chen CH, Wang JH, **Lu SN\***, Tung WC, Hung CH, Lee CM, Changchien CS. Comparison of prevalence for paraumbilical vein patency in patients with viral and alcoholic liver cirrhosis. *Am J Gastroenterol*. 2002 Sep;97(9):2415-8.
  89. **Lu SN\***, Wang JH, Kuo YK, Kuo HL, Chen TM, Tung HD, Lee CM, Chen SC. Predicting the prevalence of antibody to hepatitis C virus (HCV) in a community by the prevalence of elevated levels of alanine aminotransferase: a method to identify areas endemic for HCV. *Am J Trop Med Hyg*. 2002 Aug;67(2):145-50.
  90. Lee CM, Ong GY, **Lu SN**, Wang JH, Liao CA, Tung HD, Chen TM, Changchien CS. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. *J Hepatol*. 2002 Nov;37(5):669-74.
  91. Dai CY, Yu ML, Hou C, **Lu SN**, Wang JH, Huang JF, Chen SC, Lin ZY, Hsieh MY, Tsai JF, Wang LY, Chuang WL, Chang WY. Clinical characteristics and distribution of genotypes of TT virus infection in a hepatitis C virus-hyperendemic township of a hepatitis B virus-endemic country (Taiwan). *J Gastroenterol Hepatol* 2002 Nov; 17(11) :1192-7
  92. Hung CH, Lee CM, **Lu SN\***, Wang JH, Tung HD, Chen TM, Chen CH, Changchien CS. Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy? *J Gastroenterol Hepatol*. 2002 Dec;17(12):1307-1311.
  93. Chen TM, **Lu SN\***, Wang JH, Tung HD, Lee PL, Lee CM. The prevalence and its meaning of anti-HBc alone 15 years subsequent to mass hepatitis B vaccination. *J Int Med Taiwan* 2002 Nov; 13(5): 247-55.
  94. Chou YP, Changchien CS, Chuah SK, Chiu YC, Chou KW, Kuo CH, Hsu CC, **Lu SN**. Risk factors for mortality of esophageal perforation: a clinical experience in 32 cases. *J Int Med Taiwan* 2002 Nov; 13(5): 256-62.

95. Lee CM, Chen CH, **Lu SN**, Tung HD, Chou WJ, Wang JH, Chen TM, Hung CH, Huang CC, Chen WJ. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. *Scand J Gastroenterol* 2003 Jan;38(1):95-101.
96. Hung CH, **Lu SN\***, Wang JH, Lee CM, Chen TM, Tung HD, Chen CH, Huang WS, Changchien CS. Correlation of ultrasonographic and pathologic diagnoses for hepatitis B and C related liver cirrhosis. *J Gastroenterol* 2003 Feb; 38(2): 153-7.
97. Hung CH, Lee CM, **Lu SN**, Lee JF, Wang JH, Chen TM, Tung HD, Chen WJ, Changchien CS. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. *J Viral Hepatitis* 2003 Mar;10(2):87-94.
98. Cheng PN, Jen CM, Young KC, Chen CY, **Lu SN**, Wang CS, Chang TT. High-dose interferon  $\alpha$ 2b plus ribavirin combination therapy for GB virus-C/Hepatitis G virus infection – a study in patients with chronic hepatitis C. *Hepatogastroenterology* 2003 Mar-Apr;50(50):449-52.
99. Sun CA, Wu DM, Lin CC, **Lu SN**, You SL, Wang LY, Wu MH, Chen CJ. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. *Am J Epidemiol* 2003 Apr 15;157(8):674-82.
100. Wang LY, You SL, **Lu SN**, Ho HC, Wu MH, Sun CA, Yang HI, Chen CJ. Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. *Cancer Causes Control*. 2003 Apr;14(3):241-50.
101. Lee PL, Wang JH, **Lu SN\***, Kuo Does hepatitis C virus(HCV) infection increase the risk of Diabetes mellitus: a cross-sectional community study in an HCV-endemic village. *J Intern Med Taiwan* 2003 Apr; 14(2): 58-61.
102. **Lu SN\***, Chen TM, Lee CM, Wang JH, Tung HD, Wu JC. The molecular epidemiological and clinical aspect of hepatitis D virus in a unique triple hepatitis viruses (B, C, D) endemic community in Taiwan. *J Med Virol* 2003 May;70(1):74-80.
103. Wu KL, Changchien CS, Kuo CM, Chuah SK, **Lu SN**, Eng HL, Kuo CH. Dengue fever with acute acalculous cholecystitis. *Am J Trop Med Hyg* 2003; Jun; 68(6): 657-60.
104. Ong GY, Lee CM, **Lu SN**, Hung CH, Wang JH, Tung HD, Changchien CS. Predictor of sustained virological response to combination Therapy with interferon plus Ribavirin for Chronic hepatitis C. *J Intern Med Taiwan* 2003 Jun: 14(3): 118-23.
105. Hsu CC, **Lu SN**, Changchien CS. One-week low-dose triple therapy without anti-acid treatment has sufficient efficacy on *Helicobacter pylori* eradication and ulcer healing. *Hepatogastroenterology* 2003 Sep-Oct;50(53):1731-4.
106. Wang JH, **Lu SN\***, Changchien CS, Hwang WS, Hung CH, Tung HD, Chen TM, Lee CM. Flash echo gray-scale imaging with subtraction for assessing perfusion of small hepatocellular carcinoma. *J Clin Ultrasound* 2003 Nov;31(9):451-6.
107. Chou YP, Lee PL, Cheng YF, **Lu SN**, Changchien CS, Wang JH. Fital arterioportal shunting in a case of hepato-cellular carcinoma with spontaneous partial recession of malignant portal vein thrombosis. *Gastroenterological Journal of Taiwan* 2003 December; 20(4): 245-251.
108. Tung WC, **Lu SN\***, Wu MH, and Chen CJ. Screening of Chronic Active Hepatitis from Series of Health Examination Database. *J Intern Med Taiwan* 2004; 15: 65-75. (國內)
109. Chen CH, Eng HL, Lee CM\*, Kuo FY, **Lu SN**, Huang CM, Tung HD, Chen CL, Changchien CS. Correlations between hepatitis B virus genotype and cirrhotic or non-cirrhotic hepatoma. *Hepatogastroenterology*. 2004 Mar-Apr;51(56):552-5.
110. Kuo FY, Chen WJ, **Lu SN**, Wang JH, Eng HL\*. Fine needle aspiration cytodiagnosis of liver tumors. *Acta Cytol*. 2004 Mar-Apr;48(2):142-8.
111. Hung CH, Lee CM\*, Wang JH, Chen CH, **Lu SN**. Acute hepatitis B virus superinfection in a Taiwanese patient with chronic hepatitis C. *J Formos Med Assoc*. 2004 Apr;103(4):302-5. [case report]
112. **Lu SN**, Chow NH, Wu WC, Chang TT, Huang WS, Chen SC, Lin CH, Carr BI\*. Characteristics of hepatocellular carcinoma in a high arsenicism area in Taiwan: a case-control study. *J Occup Environ Med*. 2004 May;46(5):437-41.
113. Lee CM, Hsu CY, Eng HL, Huang WS, **Lu SN**, Changchien CS, Chen CL, Cho CL\*. Telomerase activity and telomerase catalytic subunit in hepatocellular carcinoma. *Hepatogastroenterology*. 2004 May-Jun;51(57):796-800.
114. Lee PL, Wang JH, Tung HD, Lee CM, **Lu SN\***. A higher than expected recovery rate from hepatitis C infection amongst adolescents: a community study in a hepatitis C-endemic township in Taiwan. *Trans R Soc Trop Med Hyg*. 2004 Jun;98(6):367-72.
115. Wang YH, Lin AS, Chao TY, **Lu SN**, Liu JW, Chen SS, Lin MC\*. A cluster of patients with severe acute

- respiratory syndrome in a chest ward in southern Taiwan. *Intensive Care Med.* 2004 Jun;30(6):1228-31. Epub 2004 Apr 23.
116. Ong GY, Changchien CS, Lee CM, Wang JH, Tung HD, Chuah SK, Chiu KW, Chiou SS, Cheng YF, **Lu SN\***. Liver abscess complicating transcatheter arterial embolization: a rare but serious complication. A retrospective study after 3878 procedures. *Eur J Gastroenterol Hepatol.* 2004 Aug;16(8):737-42.
  117. Wu KL, **Lu SN**, Changchien CS, Chiu KW, Kuo CH, Chuah SK, Liu JW, Lin MC, Eng HL, Chen SS, Lee CM\*, Chen CL. Sequential changes of serum aminotransferase levels in patients with severe acute respiratory syndrome. *Am J Trop Med Hyg.* 2004 Aug;71(2):125-8.
  118. Chen CH, Lee CM\*, **Lu SN**, Wang JH, Tung HD, Hung CH, Chen WJ, Changchien CS. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. *J Hepatol.* 2004 Sep;41(3):454-61.
  119. Yu SF, Wu HC, Tsai WC, Yen JH, Chiang W, Yuo CY, **Lu SN**, Chiang LC, Chen CJ\*. Detecting Epstein-Barr virus DNA from peripheral blood mononuclear cells in adult patients with systemic lupus erythematosus in Taiwan. *Med Microbiol Immunol.* 2005 May;194(3):115-20.
  120. Wu KL, Changchien CS, Kuo CH, Chiu KW, **Lu SN**, Kuo CM, Chiu YC, Chou YP, Chuah SK\*. Early abdominal sonographic findings in patients with dengue fever. *J Clin Ultrasound.* 2004 Oct;32(8):386-8.
  121. Lin KJ, Eng HL, **Lu SN**, Chiu KW, Kuo FY. Hepatic angiomyolipoma: report of two cases with emphasis on smear cytomorphology and the use of cell block with immunohistochemical stains. *Diagn Cytopathol.* 2004 Oct;31(4):263-6.
  122. **Lu SN\***, Tung HD, Chen TM, Lee CM, Wang JH, Hung CH, Chen CH, Changchien CS. Is it possible to diagnose acute hepatitis C virus (HCV) infection by a rising anti-HCV titre rather than by seroconversion? *J Viral Hepat.* 2004 Nov;11(6):563-70.
  123. Chen CH, Lee CM, Wang JH, Tung HD, Hung CH, **Lu SN\***. Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers. *Eur J Gastroenterol Hepatol.* 2004 Nov;16(11):1213-8.
  124. Chen CJ, Lin KH, Lin SC, Tsai WC, Yen JH, Chang SJ, **Lu SN**, Liu HW. High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies. *J Rheumatol.* 2005 Jan;32(1):44-7.
  125. Hung CH, Lee CM, **Lu SN**, Wang JH, Tung HD, Chen CH, Changchien CS. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. *J Gastroenterol Hepatol.* 2005 May;20(5):727-32.
  126. Yen YH, Wang JH\*, **Lu SN**, Changchien CS. Contrast-enhanced ultrasonography in hepatic angiomyolipoma. *J Ultrasound Med.* 2005 Jun;24(6):855-9.
  127. Fitzsimons D, Francois G, Hall A, McMahon B, Meheus A, Zanetti A, Duval B, Jilg W, Bocher WO, **Lu SN**, Akarca U, Lavanchy D, Goldstein S, Banatvala J, Damme PV. Related Articles, Links Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. *Vaccine.* 2005 Jul 14;23(32):4158-66. (review)
  128. Huang WS, **Lu SN\***, Wang JH, Lee CM, Tung HD, Chen TM, ChangChien CS. Prediction of viremia for cases of hepatitis C virus (HCV) infection using a third-generation anti-HCV enzyme immunoassay test. *Hepatology.* 2005 May-Jun; 52(6):893-6.
  129. Tseng PL, **Lu SN**, Tung HD, Wang JH, Changchien CS, Lee CM. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. *J Viral Hepat.* 2005 Jul; 12(4):386-92.
  130. **Lu SN**, Jiang DD, Liu JW, Lin MC, Chen CL, Su IJ, Chen SS\*. Outbreak of severe acute respiratory syndrome in southern Taiwan, 2003. *Am J Trop Med Hyg.* 2005 Aug;73(2):423-7.
  131. Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, **Lu SN\***. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. *J Gastroenterol Hepatol.* 2005 Oct;20(10):1553-9.
  132. Hsu CC, Chen JJ\*, Hu TH, **Lu SN**, Changchien CS. One-week versus two-week H2-receptor antagonist in combination with amoxicillin and tinidazole for eradication of *Helicobacter pylori* infection. *Hepatology.* 2005 Sep-Oct;52(6):1617-21.
  133. Hu ML, Liu JW, Wu KL, **Lu SN**, Chiou SS, Kuo CH, Chuah SK, Wang JH, Hu TH, Chiu KW, Lee CM\*, Changchien CS. Abnormal liver function in scrub typhus. *Am J Trop Med Hyg.* 2005 Oct;73(4):667-8.
  134. Yen YH, Chen CH, Wang JH, Lee CM, Changchien CS, **Lu SN\***. Study of hepatitis B (HB) vaccine nonresponsiveness among health care workers from an endemic area (Taiwan) *Liver International* 2005; 25: 1162–1168.
  135. Chen CH, Lee CM, **Lu SN**, Changchien CS, Eng HL, Huang CM, Wang JH, Hung CH, Hu TH. Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV

- e antigen expression in Taiwan. *J Clin Microbiol.* 2005 Dec;43(12):6000-6.
136. Chuah SK, Hu TH, Kuo CM, Chiu KW, Kuo CM, Wu KL, Chou YP, **Lu SN**, Chiou SS, Changchien CS, Eng HL. Upper Gastrointestinal Carcinoid Tumors Incidentally Found by Endoscope Examinations. *World J Gastroenterology* 2005; 11(44): 7028-32.
  137. Lee CM\*, Hung CH, **Lu SN**, Wang JH, Tung HD, Huang WS, Chen CL, Chen WJ, Changchien CS. Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan. *Intervirol.* 2006;49(1-2):76-81. Review. [SCI]
  138. Chen CH, Lee CM\*, **Lu SN**, Changchien CS, Wang JC, Wang JH, Hung CH, Hu TH. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. *J Hepatol.* 2006 Jan;44(1):76-82. [SCI]
  139. Chen CJ\*, Yang HI, Su J, Jen CL, You SL, **Lu SN**, Huang GT, Iloeje UH; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA.* 2006 Jan 4;295(1):65-73. [SCI]
  140. Chang KC, Chuah SK, Changchien CS, Tsai TL, **Lu SN**, Chiu YC, Chen YS, Wang CC, Lin JW, Lee CM, Hu TH\*. Clinical characteristics and prognostic factors of splenic abscess: a review of 67 cases in a single medical center of Taiwan. *World J Gastroenterol.* 2006 Jan 21;12(3):460-4.
  141. Kee KM, Lee CM, Wang JH, Tung HD, Changchien CS, **Lu SN\***, Wang PW. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. *J Gastroenterol Hepatol.* 2006 Jan;21(1 Pt 2):319-26. [SCI]
  142. Lee CM, Kee KM, Hung CH, Eng HL, Chang CH, Huang CM, Wang JH, Hu TH, **Lu SN**, Changchien CS, Chen WJ. Hepatic interferon receptor mRNA expression: clinical relevance and its relationship with effectiveness of interferon plus ribavirin therapy in patients with genotype 1b hepatitis C virus infection. *Antivir Ther.* 2006;11(1):17-23. [SCI]
  143. **Lu SN\***, Chen CH, Chen TM, Lee PL, Wang JH, Tung HD, Hung CH, Lee CM, Changchien CS. Hepatitis B virus infection in adolescents in a rural township--15 years subsequent to mass hepatitis B vaccination in Taiwan. *Vaccine.* 2006 Feb 6;24(6):759-65. [SCI]
  144. Wang JH, **Lu SN**, Tung HD, Changchien CS, Hung CH, Chen CH, Lee CM. Flash-echo contrast sonography in the evaluation of response of small hepatocellular carcinoma to percutaneous ablation. *J Clin Ultrasound.* 2006 May;34(4):161-8. [SCI]
  145. Yen YH, Wang JH, Hung CH, Chen CH, Tseng PL, **Lu SN\***. Gastric ulcer triggered after percutaneous ethanol injection therapy for left lobe hepatocellular carcinoma. *Liver Int.* 2006 May;26(4):502-3. [letter to the editor] [SCI]
  146. Liu JW, **Lu SN**, Chen SS, Yang KD, Lin MC, Wu CC, Boland PB, Park SY, Wong W, Tsao KC, Lin TY, Chen CL\*. Epidemiologic study and containment of a nosocomial outbreak of severe acute respiratory syndrome in a medical center in Kaohsiung, Taiwan. *Infect Control Hosp Epidemiol.* 2006 May;27(5):466-72. [SCI]
  147. Hung CH, Lee CM\*, **Lu SN**, Wang JH, Hu TH, Tung HD, Chen CH, Chen WJ, Changchien CS. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. *J Viral Hepat.* 2006 Jun;13(6):409-14. [SCI]
  148. Lee CM, **Lu SN**, Hung CH, Tung WC, Wang JH, Tung HD, Chen CH, Hu TH, Changchien CS, Chen WJ. Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications. *Trans R Soc Trop Med Hyg.* 2006 Aug;100(8):767-74. [SCI]
  149. Chen CH, Su WW, Yang SS, Chang TT, Cheng KS, Lin HH, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, **Lu SN\***. Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: analysis of 11,312 patients in Taiwan. *J Gastroenterol Hepatol.* 2006 Oct;21(10):1561-6. [SCI]
  150. Chen CH, Chang TT, Cheng KS, Su WW, Yang SS, Lin HH, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, **Lu SN\***. Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. *Liver Int.* 2006 Sep;26(7):766-73. [SCI]
  151. Wang JH\*, **Lu SN**, Hung CH, Chen TY, Chen CH, Changchien CS, Lee CM. Small hepatic nodules (< or =2 cm) in cirrhosis patients: characterization with contrast-enhanced ultrasonography. *Liver Int.* 2006 Oct;26(8):928-34. [SCI]
  152. **Lu SN**, Su WW, Yang SS, Chang TT, Cheng KS, Wu JC, Lin HH, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Chen CH\*. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. *Int J Cancer.* 2006 Oct 15;119(8):1946-52. [SCI]
  153. **Lu SN\***, Wang JH, Liu SL, Hung CH, Chen CH, Tung HD, Chen TM, Huang WS, Lee CM, Chen CC,



- Changchien CS. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. *Cancer*. 2006 Nov 1;107(9):2212-22. [SCI]
154. Hung CH, Kuo FY, Wang JH, **Lu SN**, Hu TH, Chen CH, Lee CM\*, Eng HL. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy. *Antivir Ther*. 2006;11(4):483-9. [SCI]
  155. Hung CH, Lee CM\*, **Lu SN**, Wang JH, Chen CH, Hu TH, Kee KM, Chang KC, Tseng PL, Yen YH, Changchien CS. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. *Liver Int*. 2006 Nov;26(9):1079-86. [SCI]
  156. Chen CH, Wang JH, Lee CM\*, Hung CH, Hu TH, Wang JC, **Lu SN** and Changchien CS. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. *Antiviral Therapy* 2006; 11(6): 771-778. [SCI]
  157. Yen YH, Wang JH\*, **Lu SN**, Chen TY, Changchien CS, Chen CH, Hung CH, Lee CM. Contrast-enhanced ultrasonographic spoke-wheel sign in hepatic focal nodular hyperplasia. *Eur J Radiol*. 2006 Dec;60(3):439-44. [SCI]
  158. Chen PF, Kee KM, Chen YD, Tsai LS, Shih LY, Lin LC, Chen HH, **Lu SN\***. Village Distribution and Geographic Variations of the Prevalence of Chronic Hepatitis B, C and Hypertransaminemia: an Analysis of Adult Health Examinations in 520 Villages of Tainan County, Taiwan. *J Intern Med Taiwan* 2006; 17: 276-290.
  159. Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, **Lu SN**, Sheen IS, Chang WY, Lee CM. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicenter study in Taiwan. *Antiviral therapy* 2006 ;11:985-994.
  160. Chen CH, Wang JH, Lee CM, Hung CH, Hu TH, Wang JC, **Lu SN**, Changchien CS. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. *Antiviral Therapy* 2006; 11: 771-778.
  161. Tsai MC, Kee KM, Chen YD, Lin LC, Tsai LS, Chen HH, **Lu SN\***. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country -- geographic variations among 502 villages in southern Taiwan. *J Gastroenterol Hepatol* 2007; Jan 22(1): 92-98.
  162. Changchien CS, Wang JH, **Lu SN**, Hung CH, Chen CH, Lee CM. Liu-stain quick cytodiagnosis of ultrasound-guided fine needle aspiration in diagnosis of liver tumors. *World J Gastroenterol*. 2007 Jan 21;13(3):448-51.
  163. Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, Lin CY, **Lu SN\***. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. *Int J Cancer*. 2007 Jun 15;120(12):2650-5.
  164. Chen YC, **Lu SN**, Lin MC. Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. *Chang Gung Med J*. 2007 Jan-Feb;30(1):92-7.
  165. Tung WC, Huang YJ, Leung SW, Kuo FY, Tung HD, Wang JH, Hung CH, Lee CM, Changchien CS, Yeh SA, Sun LM, Huang EY, Hsu HC, Wang CJ, **Lu SN\***. Incidence of needle tract seeding and responses of soft tissue metastasis by hepatocellular carcinoma postradiotherapy. *Liver Int*. 2007 Mar;27(2):192-200.
  166. Hung FC, Kuo CM, Chuah SK, Kuo CH, Chen YS, **Lu SN**, Chang Chien CS. Clinical analysis of primary duodenal adenocarcinoma: an 11-year experience. *J Gastroenterol Hepatol*. 2007 May;22(5):724-8.
  167. Huang JF, Yu ML, Lee CM, Dai CY, Hou NJ, Hsieh MY, Wang JH, **Lu SN**, Sheen IS, Lin SM, Chuang WL, Liaw YF. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan. *Aliment Pharmacol Ther*. 2007 May 1;25(9):1029-37.
  168. Kao JT, Chuah SK, Huang CC, Chen CL, Wang CC, Hung CH, Chen CH, Wang JH, **Lu SN**, Lee CM, Changchien CS, Hu TH. P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection. *Liver Int*. 2007 Aug;27(6):772-81.
  169. Chen CH, Lee CM, Hung CH, Hu TH, Wang JH, Wang JC, **Lu SN**, Changchien CS. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study. *Liver Int*. 2007 Aug;27(6):806-15.
  170. Chang KC, Tai MH, Lin JW, Wang CC, Huang CC, Hung CH, Chen CH, **Lu SN**, Lee CM, Changchien CS, Hu TH. Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. *Int J Cancer*. 2007 Sep 1;121(5):1059-65.
  171. Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC, **Lu SN**, Changchien CS. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. *Gastroenterology*. 2007 Nov;133(5):1466-74.
  172. Chen CH, Wang MH, Wang JH, Hung CH, Hu TH, Lee SC, Tung HD, Lee CM, Changchien CS, Chen PF,

- Hsu MC, **Lu SN\***. Aflatoxin exposure and hepatitis C virus in advanced liver disease in a hepatitis C virus endemic area in Taiwan. *Am J Trop Med Hyg.* 2007 Oct;77(4):747-52.
173. Hu TH, Wang CC, Huang CC, Chen CL, Hung CH, Chen CH, Wang JH, **Lu SN**, Lee CM, Changchien CS, Tai MH\*. Down-regulation of tumor suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection. *Oncol Rep.* 2007 Dec;18(6):1417-26.
  174. Yen YH, **Lu SN**, Chen CH, Wang JH, Wu CM, Hung CH, Tseng PL, Hu TH, Changchien CS, Lee CM\*. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy. *Liver Int.* 2007 Dec;27(10):1349-55.
  175. Yen YH, Hung CH, Hu TH, Chen CH, Wu CM, Wang JH, **Lu SN**, Lee CM\*. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin. *Aliment Pharmacol Ther.* 2008 Jan 1;27(1):72-9.
  176. Hung CH, Chen CH, Lee CM\*, Wu CM, Hu TH, Wang JH, Yen YH, **Lu SN**. Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma. *J Viral Hepat.* 2008 Jan;15(1):58-65.
  177. Hung CH, Lee CM, Kuo FY, Jiang SR, Hu TH, Chen CH, Wang JH, **Lu SN**, Eng HL, Changchien CS. Steatosis correlates with hepatic expression of death receptors and activation of nuclear factor-kappaB in chronic hepatitis C. *Liver Int.* 2008 Mar;28(3):339-46.
  178. Changchien CS, Chen CL, Yen YH, Wang JH, Hu TH, Lee CM, Wang CC, Cheng YF, Huang YJ, Lin CY, **Lu SN\***. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. *J Gastroenterol.* 2008;43(2):159-70.
  179. Hung CH, **Lu SN**, Wang JH, Hung SF, Chen CH, Hu TH, Lee CM, Changchien CS. Identified cases of acute hepatitis C from computerized laboratory database: a hospital-based epidemiological and clinical study. *J Infect.* 2008 Apr;56(4):274-80.
  180. Wu KL, Rayner CK, Chuah SK, Changchien CS, **Lu SN**, Chiu YC, Chiu KW, Lee CM. Effects of ginger on gastric emptying and motility in healthy humans. *Eur J Gastroenterol Hepatol.* 2008 May;20(5):436-40.
  181. Lee CM, Hung CH, **Lu SN**, Changchien CS. Hepatitis C virus genotypes: clinical relevance and therapeutic implications. *Chang Gung Med J.* 2008 Jan-Feb;31(1):16-25. Review.
  182. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, **Lu SN**, Chen DS, Chen CJ. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. *Gastroenterology.* 2008 Jul;135(1):111-21.
  183. Huang CF, Huang JF, Dai CY, Yu ML, **Lu SN**, Hsieh MY, Lee LP, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL. Changing prevalence of hepatitis C virus infection among teenagers in an endemic area in Taiwan. *Trans R Soc Trop Med Hyg.* 2008 Sep;102(9):929-34.
  184. **Lu SN\***, Wang JH, Chen PF, Tung HD, Tseng PL, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen YD, Tsai LS, Chen TH. Community-based mass ultrasonographic screening of hepatocellular carcinoma among thrombocytopenic adults. *Cancer Epidemiol Biomarkers Prev.* 2008 Jul;17(7):1813-21.
  185. Tseng PL, Tai MH, Huang CC, Wang CC, Lin JW, Hung CH, Chen CH, Wang JH, **Lu SN**, Lee CM, Changchien CS, Hu TH. Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. *J Surg Oncol.* 2008 Oct 1;98(5):349-57.
  186. Kao JT, Wang JH, Hung CH, Hu TH, Lee CM, Hung SF, **Lu SN\***. Changing aetiology of liver dysfunction in the new generation of a hepatitis B and C-endemic area: cross-sectional studies on adolescents born in the first 10 years after universal hepatitis B vaccination. *Liver Int.* 2008 Nov;28(9):1298-304.
  187. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, **Lu SN**, You SL, Chen DS, Liaw YF, Chen CJ; REVEAL-HBV Study Group. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. *J Natl Cancer Inst.* 2008 Aug 20;100(16):1134-43.
  188. Chen CH, Changchien CS, Lee CM, Hung CH, Hu TH, Wang JH, Wang JC, **Lu SN**. Combined Mutations in Pre-S/Surface and Core Promoter/Precore Regions of Hepatitis B Virus Increase the Risk of Hepatocellular Carcinoma: A Case-Control Study. *J Infect Dis.* 2008 Dec 1;198 (11): 1634-42.
  189. **Lu SN\***, Yen YH, Lin CY, Kee KM, Wang JH, and ChangChien CS, Clinical Staging of Hepatocellular Carcinoma. *Journal of Chinese Oncol Soc* 2008; 24: 295-303.
  190. Lin CY, Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, **Lu SN\***. Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. *Liver Int.* 2009 Jan;29(1):74-81.
  191. Kuo YH, Wang JH, **Lu SN**, Hung CH, Wei YC, Hu TH, Chen CH, Yen YH, Lee CM, Eng HL. Natural course of hepatic focal nodular hyperplasia: A long-term follow-up study with sonography. *J Clin*

- Ultrasound. 2009 Mar-Apr;37(3):132-7.
192. Tsai MC, Chen CH, Lee CM, Chen YT, Chien YS, Hung CH, Wang JH, **Lu SN**, Yen YH, Changchien CS, Hu TH. The role of HBV genotype and core promoter and precore mutations in advanced liver disease in renal transplant recipients. *J Hepatol*. 2009 Feb;50(2):281-8.
  193. Liu CJ, Chuang WL, Lee CM, Yu ML, **Lu SN**, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. *Gastroenterology*. 2009 Feb;136(2):496-504.
  194. Yen YH, Changchien CS, Wang JH, Kee KM, Hung CH, Hu TH, Lee CM, Lin CY, Wang CC, Chen TY, Huang YJ, **Lu SN\***. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. *Dig Liver Dis*. 2009 Jun;41(6):431-41.
  195. Kao JT, Wang JH, Hung CH, Yen YH, Hung SF, Hu TH, Lee CM, **Lu SN\***. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. *Vaccine*. 2009 Mar 13;27(12):1858-62.
  196. Tai WC, Hu TH, Wang JH, Hung CH, **Lu SN**, Changchien CS, Lee CM. Clinical Implications of Alpha-fetoprotein in Chronic Hepatitis C. *J Formos Med Assoc*. 2009 Mar;108(3):210-8.
  197. Hung CH, Lee CM, Chen CH, Hu TH, Jiang SR, Wang JH, **Lu SN**, Wang PW. Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C. *Liver Int*. 2009 Aug;29(7):1086-93.
  198. Wang JH, Changchien CS, Hung CH, Eng HL, Tung WC, Kee KM, Chen CH, Hu TH, Lee CM, **Lu SN\***. FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis. *J Gastroenterol*. 2009;44(5):439-46.
  199. Huang YJ, Hsu HC, Wang CY, Wang CJ, Chen HC, Huang EY, Fang FM, **Lu SN\***. The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*. 2009 Mar 15;73(4):1155-63
  200. Wang CC, Iyer SG, Low JK, Lin CY, Wang SH, **Lu SN**, Chen CL. Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. *Ann Surg Oncol*. 2009 Jul;16(7):1832-42.
  201. Chen CJ, Yang HI, Iloeje UH; REVEAL-HBV Study Group (Liaw YF, Jen CL, You SL, Chen TH, **Lu SN**, Yeh SH, Sun CA, Chen SY, Ho SC, Lu TG, Chen CC, Chen DS, Chen PJ, Hsieh CY, Lee HS, Yang PM, Chen CH, Chen JD, Huang SP, Jan CF, How WC, Su J, Wu WP, Ou TY, Shih KC, Chung WS, Li C, Lin CG, Wang LY, Chu KE, Wu MH). Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. *Hepatology*. 2009 May;49(5 Suppl):S72-84.
  202. Chiang JC, Lin CY, Wang JH, Kee KM, Chen PF, Chen YD, Tsai LS, Chen TH, **Lu SN\***. Identifying hepatitis C virus: endemic areas and estimating the viral antibody prevalence based on the prevalence of ALT elevation. *Trans R Soc Trop Med Hyg*. 2009 Sep;103(9):917-23.
  203. Chen CH, Changchien CS, Lee CM, Tung WC, Hung CH, Hu TH, Wang JH, Wang JC, **Lu SN**. A study on sequence variations in pre-S/surface, X and enhancer II/core promoter/precore regions of occult hepatitis B virus in non-B, non-C hepatocellular carcinoma patients in Taiwan. *Int J Cancer*. 2009 Aug 1;125(3):621-9.
  204. Su WW, Chen CH, Lin HH, Yang SS, Chang TT, Cheng KS, Wu JC, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, **Lu SN\***. Geographic variations of predominantly hepatitis C virus associated male hepatocellular carcinoma townships in Taiwan: identification of potential high HCV endemic areas. *Hepatol Int*. 2009 Dec;3(4):537-43.
  205. Lu SY, Lin LH, **Lu SN**, Wang JH, Hung CH. Increased oral lichen planus in a chronic hepatitis patient associated with elevated transaminase levels before and after interferon/ribavirin therapy. *J Dent Science* 2009; 4(4): 191-197
  206. Kuo YH, **Lu SN**, Chen CL, Cheng YF, Lin CY, Hung CH, Chen CH, Changchien CS, Hsu HC, Hu TH, Lee CM, Wang JH. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. *Eur J Cancer*. 2010 Mar; 46(4): 744-751.
  207. Tung HD, Wang JH, Tseng PL, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen YD, **Lu SN\***. Neither Diabetes Mellitus nor Overweight Is a Risk Factor for Hepatocellular Carcinoma in a Dual HBV and HCV Endemic Area: Community Cross-Sectional and Case-Control Studies. *Am J Gastroenterol*. 2010 Mar;105(3):624-31.
  208. Chang KC, Tsai PS, Hsu MC, Hung SF, Tsai CC, **Lu SN\***. Chronic hepatitis C increased the mortality rates of patients with hepatocellular carcinoma and diabetes mellitus in a triple hepatitis virus endemic community. *J Gastroenterol*. 2010 Jun;45(6):636-45.
  209. Tsai MC, Wang JH, Hung CH, Kee KM, Yen YH, Lee CM, Hu TH, Chen CH, **Lu SN\***. Favorable alpha-

- fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. *J Gastroenterol Hepatol*. 2010 Mar;25(3):605-12.
210. Lin LH, Lu SY, **Lu SN**. Seroprevalence of anti-HCV among patients with oral lichen planus in Southern Taiwan. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2010 Mar; 109(3): 408-14.
  211. Chen CH, Lee CM, Tung WC, Wang JH, Hung CH, Hu TH, Wang JC, **Lu SN**, Changchien CS. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. *J Hepatol*. 2010 Apr;52(4):478-85
  212. Chen JD, Yang HI, Iloeje UH, You SL, **Lu SN**, Wang LY, Su J, Sun CA, Liaw YF, Chen CJ; for the Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (the REVEAL-HBV) Study Group. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. *Gastroenterology*. 2010 May; 138(5): 1747-54.
  213. Wang JH, Changchien CS, Hung CH, Tunf WC, Kee KM, Chen CH, Hu TH, Lee CM, **Lu SN\***. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: a longitudinal study using FibroScan. *J Gastroenterol Hepatol* 2010 May; 25 (5) 964-9.
  214. Chang CJ, Chiang JC, **Lu SN**, Wang JH. Hepatitis Delta Virus and GBV-C Infection in Two nearby Hepatitis B Virus and Hepatitis C Virus-Endemic Villages in Taiwan *Chang Gung Med J* 2010 Mar-Apr; 33(2): 137-44.
  215. Kuo YH, Chen CH, Wang JH, Hung CH, Tseng PL, **Lu SN**, Changchien CS, Lee CM. Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. *Scand J Gastroenterol*. 2010;45(1):75-81.
  216. Chen CH, Lee CM, Chen CH, Hu TH, Wang JH, Hung CH, Chung CH, **Lu SN**. Prevalence and clinical relevance of serum autoantibodies in patients with chronic hepatitis C. *Chang Gung Med J* 2010 May-Jun; 33(3):258-65.
  217. Chen JY, Chiang JC, **Lu SN**, Hung SF, Kao JD, Yen YH, Wang JH. Changing Prevalence of Anti-Hepatitis A Virus (HAV) of Adolescents in a Rural Township in Taiwan. *Chang Gung Med J* 2010 May-Jun; 33(3): 321-6.
  218. Hung CH, Wang JH, Hu TH, Chen CH, Chang KC, Yen YH, Kuo YH, Tsai MC, **Lu SN**, Lee CM. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. *World J Gastroenterol*. 2010 May 14;16(18):2265-71.
  219. Yu ML, Lee CM, Chuang WL, **Lu SN**, Dai CY, Huang JF, Lin ZY, Hu TH, Chen CH, Hung CH, Wang JH, Chen CL, Kao JH, Lai MY, Liu CH, Su TH, Wu SS, Liao LY, Kuo HT, Chao YC, Tung SY, Yang SS, Chen PJ, Liu CJ, Chen DS. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. *J Infect Dis*. 2010 Jul 1;202(1):86-92.
  220. Liu J, Yang HI, Lee MH, **Lu SN**, Jen CL, Wang LY, You SL, Iloeje UH, Chen CJ; R.E.V.E.A.L.-HBV Study Group. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. *Gastroenterology* 2010 Aug;139 (2):474-82.
  221. Lee JJ, Lin MY, Yang YH, **Lu SN**, Chen HC, Hwang SJ. Association of Hepatitis C and B Virus Infection With CKD in an Endemic Area in Taiwan: A Cross-sectional Study. *Am J Kidney Dis*. 2010 Jul;56(1):23-31.
  222. Kee KM, Hung CM, Wang JH, Hung CH, Chen PF, Lin KS, **Lu SN\***. Low accuracy of the national reporting system of acute hepatitis C infection in Taiwan, 1995 ~ 2004 *J Gastroenterol Hepatol*. 2010 Jul;25(7):1289-94.
  223. Tseng PL, Wang JH, Tung HD, Hung CH, Kee KM, Chen CH, Chang KC, Lee CM, Changchien CS, Chen PF, Tsai LS, **Lu SN\***. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. *J Gastroenterol Hepatol*. 2010 Aug;25(8):1426-34.
  224. Hung CH, Lee CM, **Lu SN**, Wang JH, Chen CH, Hu TH. Hepatic steatosis with hepatitis B virus/hepatitis C virus dual infection. *Hepatology*. 2010 Oct;52(4):1521-2.
  225. Yang TS, **Lu SN#**, Chao Y, Sheen IS, Lin CC, Wang TE, Chen SC, Wang JH, Liao LY, Thomson JA, Wang-Peng J, Chen PJ, Chen LT. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. *Br J Cancer*. 2010 Sep 28;103(7):954-60. (#: Co-first author)
  226. Hsu RF, Ho CK, **Lu SN**, Chen SS. Predicting hearing thresholds and occupational hearing loss with multiple-frequency auditory steady-state responses. *J Otolaryngol Head Neck Surg*. 2010 Oct;39(5):504-10.
  227. Lee MH, Yang HI, **Lu SN**, Jen CL, Yeh SH, Liu CJ, Chen PJ, You SL, Wang LY, Chen WJ, Chen CJ. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. *J Clin Oncol*. 2010 Oct 20;28(30):4587-93.
  228. Chen JY, Wang JH, Lin CY, Chen PF, Tseng PL, Chen CH, Chang KC, Tsai LS, Chen SC, **Lu SN\*** Lower prevalence of hypercholesterolemia and hyperglyceridemia found in subjects with seropositivity for both

- Hepatitis B and C strains independently *J Gastroenterol Hepatol* 2010 Nov;25(11):1763-8.
229. Kuo YH, [Lu SN](#), Hung CH, Kee KM, Chen CH, Hu TH, Lee CM, Changchien CS, Wang JH. Liver stiffness measurement in the risk assessment of hepatocellular carcinoma for patients with chronic hepatitis. *Hepatol Int* 2010 Dec; 4(4): 700-706.
  230. Huang YC, Huang CF, Chang KC, Hung SF, Wang JH, Hung CH, Chen, CH, Tseng PL, Kee KM, Yen YH, Tsai PS, Tsai CC, [Lu SN\\*](#). Community-based screening for hepatocellular carcinoma in elderly residents in a hepatitis B and C endemic area. *J Gastroenterol Hepatol* 2011 Jan;26(1):129-134.
  231. Chen CH, Lee CM, Hung CH, Wang JH, Hu TH, Changchien CS, [Lu SN\\*](#). Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients. *J Gastroenterol Hepatol* 2011 Mar;26(3):461-8.
  232. Chen CT, Kuo YH, Huang CF, [Lu SN\\*](#). Treatment Effects of Standard of Care for Chronic Hepatitis C in Real World: A Personal Experience of A Hepatologist in A Medical Center in Southern Taiwan. *J Intern Med Taiwan* 2011; 22: 192-198. (non-SCI)
  233. Hung CH, Lee CM, Wang JH, Hu TH, Chen CH, Lin CY, [Lu SN\\*](#). Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. *Int J Cancer*. 2011 May 15;128(10):2344-52.
  234. Wang JH, Tung HD, Chen TY, Hung CH, Chen CH, Changchien CS, Hu TH, Lee CM, [Lu SN\\*](#). Radiofrequency ablation of small hepatocellular carcinoma with intravenous pegylated liposomal doxorubicin. *Hepatol Int* 2010 Sep 18;5(1):567-74.
  235. Chang Y, Lairson DR, Chan W, [Lu SN](#), Aoki N. Cost-effectiveness of screening for hepatocellular carcinoma among subjects at different levels of risk. *J Eval Clin Pract*. 2011 Apr;17(2):261-7.
  236. Tsai PS, Chang CJ, Chen KT, Chang KC, Hung SF, Wang JH, Hung CH, Chen CH, Tseng PL, Kee KM, Yen YH, Tsai CC, [Lu SN\\*](#). Acquisition and disappearance of HBsAg and anti-HCV in an aged population: a follow-up study in an endemic township. *Liver Int*. 2011 Aug;31(7):971-9.
  237. Lee MH, Yang HI, Jen CL, [Lu SN](#), Yeh SH, Liu CJ, You SL, Sun CA, Wang LY, Chen WJ, Chen CJ; for the R.E.V.E.A.L.–HCV Study Group. Community and personal risk factors for hepatitis C virus infection: a survey of 23 820 residents in Taiwan in 1991-2. *Gut*. 2011 May;60(5):688-94..
  238. Chen CH, Wang JH, [Lu SN](#), Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM. Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience. *Liver Int*. 2011 Feb;31(2):206-14.
  239. Chang KC, [Lu SN](#), Chen PF, Hung CF, Kee KM, Wang JH. Incidence and Associated Risk Factors of Hepatocellular Carcinoma in a Dural Hepatitis B and C Virus Endemic Area: A Surveillance Study. *Kaohsiung J Med Sci* 2011 Mar;27(3):85-90.
  240. Xu HW, Wang JH, Tsai MS, Wu KL, Chiou SS, Changchien CS, Hu TH, [Lu SN](#), Chuah SK. The effects of cefazolin on cirrhotic patients with acute variceal hemorrhage after endoscopic interventions. *Surg Endosc*. 2011 Sep;25(9):2911-8.
  241. Hung CH, Lee CM, [Lu SN\\*](#). Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. *Expert Rev Anti Infect Ther*. 2011 May;9(5):525-33. Review.
  242. Yeh ML, Hung CH, Huang JF, Liu CJ, Lee CM, Dai CY, Wang JH, Lin ZY, [Lu SN](#), Hu TH, Yu ML, Kao JH, Chuang WL, Chen PJ, Chen DS. Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. *PLoS One*. 2011;6(6):e20752.
  243. Kuo YH, Chuang TW, Hung CH, Chen CH, Wang JH, Hu TH, [Lu SN](#), Lee CM. Reversal of hypolipidemia in chronic hepatitis C patients after successful antiviral therapy. *J Formos Med Assoc*. 2011 Jun;110(6):363-71.
  244. Hsu RF, Chen SS, [Lu SN](#), Ho CK, Lin HF. Dichotic multiple-frequency auditory steady-state responses in evaluating the hearing thresholds of occupational noise-exposed workers. *Kaohsiung J Med Sci*. 2011 Aug;27(8):330-5.
  245. Huang YT, Jen CL, Yang HI, Lee MH, Su J, [Lu SN](#), Iloeje UH, Chen CJ. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. *J Clin Oncol*. 2011 Sep 20;29(27):3643-50.
  246. Lee CM, Yen YH, Hung CH, [Lu SN](#), Wang JH, Wang JC, Chen CH, Kee KM, Hu TH, Changchien CS. Liver interleukin-8 messenger RNA expression and interferon sensitivity-determining region mutations relate to treatment response in hepatitis C 1b. *Antivir Ther*. 2011;16(6):825-32.
  247. Carr BI, [Lu SN](#), Pancoska P. Small hepatocellular carcinoma in Chinese patients. *Hepatogastroenterology*. 2011 Jul-Aug;58(109):1334-42.
  248. Xu HW, Wu KL, Wang JH, Tsai MS, Hung CH, Chiou SS, Changchien CS, Hu Th, [Lu SN](#), Chuah SK, Comparison of cefazolin and ceftriaxone as prophylactic antibiotic in cirrhotic patients with acute variceal

- hemorrhage after endoscopic interventions. *Gastroenterol J Taiwan*. 2011; 28(3): 289-298
249. Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, Su J, Hsiao CK, Wang LY, You SL, **Lu SN**, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (REVEAL-HBV) Study Group. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. *Gastroenterology*. 2011 Oct;141(4):1240-8
250. Hung CH, **Lu SN**, Wang JH, Hu TH, Chen CH, Huang CM, Lee CM. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients. *Antivir Ther*. 2011;16(7):959-68.
251. Kee KM, **Lu SN\***. Hospital- and community- based screenings for hepatocellular carcinoma in Taiwan. *Oncology* 2011;81(suppl 1):36-40. [Review]

#### 最近五年發表論文

252. Wang JH, Wang CC, Hung CH, Chen CL, **Lu SN\***. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. *J Hepatol*. 2012 Feb;56(2):412-8. (SCI)
253. Hung CH, Chen CH, **Lu SN**, Wang JH, Hu TH, Huang CM, Tsai MC, Lee CM. Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy. *Antiviral Res*. 2012 Jan;93(1):55-63. (SCI)
254. Tsai MC, Lee CM, Chiu KW, Hung CH, Tung WC, Chen CH, Tseng PL, Chang KC, Wang JH, **Lu SN**, Yen YH, Hu TH. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. *J Antimicrob Chemother*. 2012 Mar;67(3):696-9. (SCI)
255. Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, Chang KC, Tseng PL, Yen YH, Lin CY, **Lu SN\***. Decreased anti-HCV titer and associated factors in chronic hepatitis C patients after sustained virological response: A prospective study. *J Gastroenterol Hepatol*. 2012 Jun;27(6):1106-11. (SCI)
256. Yang HI, Hung HL, Lee MH, Liu J, Jen CL, Su J, Wang LY, **Lu SN**, You SL, Iloeje UH, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/cancer-HBV (REVEAL-HBV) Study Group. Incidence and determinants of spontaneous seroclearance of hepatitis B e antigen and DNA in patients With chronic Hepatitis B. *Clin Gastroenterol Hepatol*. 2012 May;10(5):527-34.e1-2. (SCI)
257. Chen CH, Wang JH, **Lu SN**, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants. *Antivir Ther*. 2012;17(4):701-9. (SCI)
258. Wang JH, Chuah SK, **Lu SN**, Hung CH, Chen CH, Kee KM, Chang KC, Tai WC, Hu TH. Transient elastography and simple blood markers in diagnosis of oesophageal varices for compensated patients with hepatitis B virus-related cirrhosis. *J Gastroenterol Hepatol*. 2012 Jul;27(7):1213-8. (SCI)
259. Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, Chen CH, **Lu SN\***. Is HCV core antigen (HCV Ag) an adequate marker for community screening? *J Clin Microbiol*. 2012 Jun;50(6):1989-93. (SCI)
260. **Lu SN**. Cross-stage and combination treatment for Barcelona Clinic of Liver Cancer stage B (intermediate stage) hepatocellular carcinoma. *J Gastroenterol Hepatol*. 2012 Jun;27(6):991-3. [Editorial] (SCI)
261. Lee MH, Yang HI, **Lu SN**, Jen CL, You SL, Wang LY, Wang CH, Chen WJ, Chen CJ; for the R.E.V.E.A.L.-HCV Study Group. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic Diseases: a community-based long-term prospective study. *J Infect Dis*. 2012 Aug; 206(4):469-477. (SCI)
262. Chiang CH, Yang HI, Jen CL, Lu SN, Wang LY, You SL, Su J, Iloeje UH, Chen CJ. Association between obesity, hypertriglyceridemia and low hepatitis B viral load. *Int J Obes (Lond)*. 2013 Mar;37(3):410-5. (SCI)
263. Liu JL, Chen JY, Chen CT, Wang JH, Lin CY, Chen PF, Hung CH, Kee KM, Lee CM, Tsai LS, Chen SC, Lin SC, **Lu SN\***. A Community-Based Cross-Sectional Study: The Association of Lipids with Hepatitis C Seropositivity and Diabetes Mellitus. *J Gastroenterol Hepatol*. 2012 Nov;27(11):1688-94. (SCI)
264. Kee KM, Wang JH, Hung CH, Chen CH, Lee CM, **Lu SN\***. Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response. *Dig Dis Sci*. 2013 Feb;58(2):556-61. (SCI)
265. Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, Kuo YH, Tsai MC, Hung CH, Chen CH, Tai WC, Tsai LS, Chen SC, Lin SC, **Lu SN\***. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. *Am J Gastroenterol*. 2013 Mar;108(3):416-24. (SCI)
266. Chang KC, Hung CH, **Lu SN**, Wang JH, Lee CM, Chen CH, Yen MF, Lin SC, Yen YH, Tsai MC, Tseng PL, Hu TH. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. *J Antimicrob Chemother*. 2012 Nov;67(11):2766-72. (SCI)

267. Xu HW, **Lu SN**, Hung CH, Chang KC, Hu TH, Wang JH. Liver stiffness measurement in cirrhotic patient -- implications of disease activity and treatment efficacy. *Kaohsiung J Med Sci.* 2012 Dec;28(12):641-8. (SCI)
268. Liu J, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, **Lu SN**, Wang LY, You SL, Hsiao CK, Yang HI, Chen CJ. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. *J Hepatol.* 2013 May;58(5):853-60. (SCI)
269. Lin HF, Lai YC, Tai CF, Tsai JL, Hsu HC, Hsu RF, **Lu SN**, Feng NH, Chai CY, Lee CH. Effects of cultured human adipose-derived stem cells transplantation on rabbit cornea regeneration after alkaline chemical burn. *Kaohsiung J Med Sci.* 2013 Jan;29(1):14-8. (SCI)
270. Hsieh YC, Yap YS, Hung CH, Chen CH, **Lu SN**, Wang JH. Factors related to postoperative pain among patients who underwent radiofrequency ablation of hepatocellular carcinoma. *Clin Radiol.* 2013 Jun;68(6):600-7. (SCI)
271. Wang HM, Hung CH, **Lu SN**, Chen CH, Lee CM, Hu TH, Wang JH. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients. *Liver Int.* 2013 May;33(5):756-61. (SCI)
272. Lin YJ, Lee MH, Yang HI, Jen CL, You SL, Wang LY, **Lu SN**, Liu J, Chen CJ. Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. *PLoS One.* 2013 Apr 17;8(4):e61448. (SCI)
273. Wu CK, Wang JH, Lee CH, Wu KL, Tai WC, **Lu SN**, Hu TH, Chuah SK. The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after endoscopic interventions for acute variceal hemorrhage. *PLoS One.* 2013 Apr 22;8(4):e61666. (SCI)
274. Hung CH, Chang KC, **Lu SN**, Wang JH, Chen CH, Lee CM, Hu TH. Spontaneous clearance of hepatitis C virus in an interleukin 28B favorable genotype- highly prevalent area. *Hepatology.* 2013 May; 57(5): 2089-90. (SCI)
275. Yang SC, Wu KL, Wang JH, Lee CH, Kuo YH, Tai WC, Chen CH, Chiou SS, **Lu SN**, Hu TH, Changchien CS, Chuan SK. The effect of systemic antibiotic prophylaxis for cirrhotic patients with peptic ulcer bleeding after endoscopic interventions. *Hepatol Int.* 2013 Mar;7(1):257-67. (SCI)
276. Chen CH, Lee CM, Wang JH, Hu TH, Hung CH, Changchien CS, **Lu SN**\*. Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion. *Hepatol Int.* 2013 Jun;7(2):477-88. (SCI)
277. Yang SC, **Lu SN**, Lee CM, Hu TH, Wang JH, Hung CH, Changchien CS, Chen CH. Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg seroconversion. *Hepatol Int* 2013; 7(2): 489-499. (SCI)
278. Chen CH, Hu TH, Hung CH, **Lu SN**, Wang JH, Chang MH, Changchien CS, Lee CM. A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients. *Hepatol Int* 2013; 7(3): 832-843. (SCI)
279. Tseng PL, Wang JH, Hung CH, Dung HD, Chen TM, Hung WS, Liu HL, Hu TH, Lee CM, **Lu SN**\*. Comparisons of non-invasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations. *Kaohsiung J Med Sci* 2013 July; 29 (7): 385-95. (SCI)
280. Chen CT, Chen JY, Wang JH, Chang KC, Tseng PL, Kee KM, Chen PH, Tsai LS, Chen SC, Lin SC, **Lu SN**\*. Diabetes mellitus, metabolic syndrome, and obesity are not significant risk factors for hepatocellular carcinoma in an HBV- and HCV-endemic area of Southern Taiwan. *Kaohsiung J Med Sci* 2013 Aug; 29 (8): 451-9. (SCI)
281. Wang JH, Kuo YH, Wang CC, Chen CL, Cheng YF, Hsu HC, **Lu SN**. Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C. *Dig Liver Dis.* 2013 Jun; 45(6):510-5. (SCI)
282. Yu ML, Lee CM, Chen CL, Chuang WL, **Lu SN**, Liu CH, Wu SS, Liao LY, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Su WW, Lin CL, Yang HC, Chen PJ, Chen DS, Liu CJ; for the Taiwan Liver-Net Consortium. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. *Hepatology.* 2013 Jun; 57(6): 2135-42. (SCI)
283. Hung CH, Hu TH, Lee CM, Huang CM, Chen CH, Wang JH, **Lu SN**. Amino acid substitutions in the core region associate with insulin resistance in chronic hepatitis C. *Intervirology.* 2013; 56(3):166-71. (SCI)
284. Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, **Lu SN**, You SL, Wang LY, Chen CJ; for the R.E.V.E.A.L.-HBV Study Group. Prediction models of long-term cirrhosis and HCC risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles. *Hepatology.* 2013 Aug; 58(2):546-54. (SCI)

285. Kee KM, Wang JH, Lin CY, Wang CC, Cheng YF, **Lu SN\***. Validation of 7th edition TNM staging system for Hepatocellular carcinoma: An analysis of 8828 patients in a single medical center. *Dig Dis Sci*. 2013 Sep;58(9):2721-8. (SCI)
286. Tsai MC, Chen CH, Hung CH, Lee CM, Chiu KW, Wang JH, **Lu SN**, Tseng PL, Chang KC, Yen YH, Hu TH\*. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. *Clin Microbiol Infect*. 2014 Feb;20(2):090-0100. (SCI)
287. Yang SC, Lee CM, Hu TH, Wang JH, **Lu SN**, Hung CH, Changchien CS, Chen CH. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. *J Antimicrob Chemother*. 2013 Sep;68(9):2154-63. (SCI)
288. Pancoska P, **Lu SN**, Carr BI. Phenotypic Categorization and Profiles of Small and Large Hepatocellular Carcinomas. *J Gastrointest Dig Syst*. 2013 Mar 2;Suppl 12.
289. Hung CH, Chen CH, Lee CM, Hu TH, **Lu SN**, Wang JH, Huang CM. Role of viral genotypes and hepatitis B viral mutants in the risk of hepatocellular carcinoma associated with hepatitis B and C dual infection. *Intervirology*. 2013;56(5):316-24. (SCI)
290. Loomba R, Liu J, Yang HI, Lee MH, **Lu SN**, Wang LY, Iloeje UH, You SL, Brenner D, Chen CJ; REVEAL-HBV Study Group. Synergistic Effects of Family History of Hepatocellular Carcinoma and Hepatitis B Virus Infection on Risk for Incident Hepatocellular Carcinoma. *Clin Gastroenterol Hepatol*. 2013 Dec;11(12):1636-45. (SCI)
291. Chen DS, Locarnini S, Wait S, Bae SH, Chen PJ, Fung JY, Kim HS, **Lu SN**, Sung J, Tanaka J, Wakita T, Ward J, Wallace J; CEVHAP North Asia Workshop on Viral Hepatitis. Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia. *J Hepatol*. 2013 Nov;59(5):1073-80. (SCI)
292. Wang JH, Hung CH, Kuo FY, Eng HL, Chen CH, Lee CM, **Lu SN**, Hu TH. Ultrasonographic quantification of hepatic-renal echogenicity difference in hepatic steatosis diagnosis. *Dig Dis Sci*. 2013 Oct;58(10):2993-3000. (SCI)
293. Wang JH, **Lu SN\***. Response to Giannini et al. *Am J Gastroenterol*. 2013 Jul;108(7):1175. (SCI)
294. Chang KC, Wu YY, Hung CH, **Lu SN**, Lee CM, Chiu KW, Tsai MC, Tseng PL, Huang CM, Cho CL, Chen HH, Hu TH. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. *Br J Cancer*. 2013 Oct 29;109(9):2481-8. (SCI)
295. Yen YH, Wang JC, Hung CH, **Lu SN**, Wang JH, Hu TH, Kee KM, Hsiao CC\*, Lee CM\*. Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin. *J Formos Med Assoc*. 2015 Jul;114(7):652-8. (SCI)
296. Lee CM, Chen CY, Chien RN, Tseng KC, Peng CY, Tung SY, Fang YJ, Huang YH, **Lu SN**, Hung CH, Tsai TJ, Fang CC, Hsu CW, Yeh CT\*. A Double-Blind Randomized Controlled Study to Evaluate the Efficacy of Low-Dose Oral Interferon-Alpha in Preventing Hepatitis C Relapse. *J Interferon Cytokine Res*. 2014 Mar;34(3):187-94. (SCI)
297. Liu J, Yang HI, Lee MH, **Lu SN**, Jen CL, Batrla-Utermann R, Wang LY, You SL, Hsiao CK, Chen PJ, Chen CJ; for the R.E.V.E.A.L.-HBV Study Group. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. *Gut*. 2014 Oct;63(10):1648-57. (SCI)
298. Liang CM, Hu TH, **Lu SN**, Hung CH, Huang CM, Wang JH, Yen YH, Chen CH, Chang KC, Tsai MC, Kuo YH, Lee CM. Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy. *J Viral Hepat*. 2013 Nov;20(11):761-9. (SCI)
299. Lee MH, Yang HI, **Lu SN**, Jen CL, You SL, Wang LY, L'italien G, Chen CJ, Yuan Y; for the REVEAL-HCV Study Group. Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. *Int J Cancer*. 2014 Sep 1;135(5):1119-26. (SCI)
300. Chen CH, Lin CL, Hu TH, Hung CH, Tseng PL, Wang JH, Chang JY, **Lu SN**, Chien RN, Lee CM\*. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. *J Hepatol*. 2014 Jun;60(6):1127-34. (SCI)
301. Wang JH\*, Chuah SK, **Lu SN**, Hung CH, Kuo CM, Tai WC, Chiou SS. Baseline and serial liver stiffness measurement in prediction of portal hypertension progression for patients with compensated cirrhosis. *Liver Int*. 2014 Oct;34(9):1340-8. (SCI)
302. Kuo YH, **Lu SN**, Chen CH, Chang KC, Hung CH, Tai WC, Tsai MC, Tseng PL, Hu TH, Wang JH\*. The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy. *PLoS One*. 2014 Mar 28;9(3):e93160. (SCI)
303. Liu J, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, **Lu SN**, Wang LY, You SL, Hsiao CK, Chen CJ; REVEAL-HBV Study Group. Distinct seromarkers predict different milestones of chronic hepatitis B progression. *Hepatology*. 2014 Jul;60(1):77-86. (SCI)



304. Chen CH, Hu TH, Hung CH, Wang JH, **Lu SN**, Lee CM\*. Antiviral effect of entecavir in nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy. *J Viral Hepat.* 2014 Aug;21(8):e55-64. (SCI)
305. Yang SC, Chen JC, Tai WC, Wu CK, Lee CH, Wu KL, Chiu YC, Wang JH, **Lu SN**, Chuah SK\*. The influential roles of antibiotics prophylaxis in cirrhotic patients with peptic ulcer bleeding after initial endoscopic treatments. *PLoS One.* 2014 May 2;9(5):e96394. (SCI)
306. Chen CH, **Lu SN**, Hung CH, Wang JH, Hu TH, Changchien CS, Lee CM\*. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. *J Hepatol.* 2014 Sep;61(3):515-22. (SCI)
307. Lee MH\*, **Lu SN**\*, Yuan Y, Yang HI, Jen CL, You SL, Wang LY, L'Italien G, Chen CJ\*; R.E.V.E.A.L.-HCV Study Group. Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. *PLoS One.* 2014 May 6;9(5):e94760. (Co-Corresponding author) (SCI)
308. Kuo LF, Lee CM, Hung CH, Wang JH, Hu TH, **Lu SN**, Changchien CS, Chen CH\*. High risk of hepatitis B virus reactivation in nucleos(t)ide analogue-induced hepatitis B e antigen seroconverters older than 40 years. *Dig Dis Sci.* 2014 Oct;59(10):2580-7. (SCI)
309. Hung CH\*, Chiu YC, Hu TH, Chen CH, **Lu SN**, Huang CM, Wang JH, Lee CM. Significance of vitamin d receptor gene polymorphisms for risk of hepatocellular carcinoma in chronic hepatitis C. *Transl Oncol.* 2014 Aug;7(4):503-7. (SCI)
310. Chen CL, Yang WS, Yang HI, Chen CF, You SL, Wang LY, **Lu SN**, Liu CJ, Kao JH, Chen PJ, Chen DS, Chen CJ. Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: a prospective study in taiwan. *Cancer Epidemiol Biomarkers Prev.* 2014 Aug;23(8):1659-71. (SCI)
311. Kee KM, Hung CH, Wang JH, **Lu SN**\*. Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib. *Onco Targets Ther.* 2014 May 27;7:829-34. (SCI)
312. Yap AQ, Millan CA, Wang JH, Wang CC\*, **Lu SN**, Wang SH, Lin CC, Liu YW, Yong CC, Li WF, Lin TL, Chen CL. How to improve the outcome in patients with AJCC stage I hepatocellular carcinoma. *Anticancer Res.* 2014 Jun;34(6):3093-103. (SCI)
313. Ma MC, Chen YY, Li SH, Cheng YF, Wang CC, Chiu TJ, Pei SN, Liu CT, Huang TL, Huang CH, Su YL, Chen YH, **Lu SN**, Rau KM\*. Intra-arterial chemotherapy with doxorubicin and cisplatin is effective for advanced hepatocellular cell carcinoma. *ScientificWorldJournal.* 2014;2014:160138.
314. Chen CH, Chiu YC, **Lu SN**, Lee CM, Wang JH, Hu TH, Hung CH\*. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. *World J Gastroenterol.* 2014 Jun 28;20(24):7686-95. (SCI)
315. Carr BI\*, Lin CY, **Lu SN**. Platelet-related phenotypic patterns in hepatocellular carcinoma patients. *Semin Oncol.* 2014 Jun;41(3):415-21. (SCI)
316. Wang JH, Kee KM, Lin CY, Hung CH, Chen CH, Lee CM, **Lu SN**\*. Validation and modification of a proposed sub-staging system for patients with intermediate hepatocellular carcinoma. *J Gastroenterol Hepatol.* 2015 Feb;30(2):358-63. (SCI)
317. Liu J, Tseng TC, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, **Lu SN**, Wang LY, You SL, Chen PJ, Chen CJ, Kao JH. Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System. *J Infect Dis.* 2015 May15;211(10):1566-73. (SCI)
318. Kuo YH, Chung KC, Hung CH, **Lu SN**, Wang JH\*. The impact of general anesthesia on radiofrequency ablation of hepatocellular carcinoma. *Kaohsiung J Med Sci.* 2014 Nov;30(11):559-65. (SCI)
319. Chang KC, Tseng PL, Wu YY, Hung HC, Huang CM, **Lu SN**, Wang JH, Lee CM, Chen CH, Tsai MC, Yen YH, Lin MT, Wu CK, Huang CC, Chen HH, Hu TH\*. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection. *Clin Gastroenterol Hepatol.* 2015 May;13(5):1017-24. (SCI)
320. Kuo MT, Hu TH, **Lu SN**, Hung CH\*, Wang JH, Chen CH, Chiu YC, Lee CM. Neutrophil-to-lymphocyte ratio as a predictor of response to peginterferon plus ribavirin therapy for chronic hepatitis C. *Dis Markers.* 2014;2014:462958. (SCI)
321. Chen CH\*, **Lu SN**, Lee CM, Hung CH, Wang JH, Hu TH. Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion. *Hepatol Int.* 2014 Jul;8(3):365-74. (SCI)
322. Yao CC, Lee CM, Hung CH, Wang JH, Hu TH, **Lu SN**, Changchien CS, Hsu MC, Chen CH\*. Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion. *J Gastroenterol Hepatol.* 2015 May;30(5):918-24. (SCI)

323. Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, **Lu SN\***. Changing serum levels of quantitative hepatitis B surface antigen and hepatitis B virus DNA in hepatitis B virus surface antigen carriers: a follow-up study of an elderly cohort. *Kaohsiung J Med Sci.* 2015 Feb;31(2):102-7. (SCI)
324. Hung CH, Hu TH, **Lu SN**, Lee CM, Chen CH, Kee KM, Wang JH, Tsai MC, Kuo YH, Chang KC, Chiu YC, Chen CH\*. Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation. *Antimicrob Agents Chemother.* 2015;59(6):3168-73. (SCI)
325. Carr BI, Guerra V, Steel JL, **Lu SN**. A comparison of patients with hepatitis B-or hepatitis C-based advanced-stage hepatocellular carcinoma. *Semin Oncol.* 2015 Apr;42(2):309-15. (SCI)
326. Kuo YH, Chen PF, Wang JH, Chang KC, Kee KM, Tsai MC, Lin CY, Lin SC, Tsai LS, Chen SC, **Lu SN\***. Comparison Stratagems of Post-Screening Management of Anti-HCV-Positive Community Residents: Simple Notification, Active Referral, or Accessible Medical Care. *PLoS One.* 2015 May 13;10(5):e0126031. (SCI)
327. Kuo YH, **Lu SN\***. Role of serum quantitative hepatitis B surface antigen (HBsAg) in HBsAg carriers in a follow-up community study. *Kaohsiung J Med Sci.* 2015 Jul;31(7):386-7. (SCI)
328. Chen CH, Hung CH, Hu TH, Wang JH, **Lu SN**, Su PF, Lee CM\*. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection. *Clin Gastroenterol Hepatol.* 2015 Nov;13(11):1984-1992. (SCI)
329. Lee MH, Yang HI, **Lu SN**, Lin YJ, Jen CL, Wong KH, Chan SY, Chen LC, Wang LY, L'Italien G, Yuan Y, Chen CJ. Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk. *Sci Rep.* 2015 Nov 25;5:17030. (SCI)
330. Yeh JH, Hung CH, Wang JH, Chen CH, Kee KM, Kuo CM, Yen YH, Cheng YF, Chen YY, Hsu HC, **Lu SN\***. Modifiable Prognostic Factors of Hepatocellular Carcinoma in Patients with Non-Surgical Treatment. *PLoS One.* 2015 Dec 14;10(12):e0144893. (SCI)
331. Yap YS, Chuang KW, Chiang CJ, Chuang HY, **Lu SN\***. Geographic Variation of Chronic Kidney Disease Prevalence: Correlation with the Incidence of Renal Cell Carcinoma or Urothelial Carcinoma? *Biomed Res Int.* 2015;2015:427084. (SCI)
332. Lu SY\*, Tsai CY, Lu SN, Lin LH. Is alteration of warfarin regimen necessary before dental extractions in Taiwanese patients? Results of a retrospective cohort study. *Journal of Dental Sciences.* 2015 Dec. 10(4): 352-358. (SCI)
333. Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Wang JH, **Lu SN**, Lee CM, Chang KC, Yen YH, Lin MT, Chou YP, Hu TH\*. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. *Clin Microbiol Infect.* 2016 Jan;22(1):95.e1-7. (SCI)
334. Hung CH\*, Hu TH, **Lu SN**, Kuo FY, Chen CH, Wang JH, Huang CM, Lee CM, Lin CY, Yen YH, Chiu YC. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus. *Int J Cancer.* 2016 Feb 1;138(3):714-20. (SCI)
335. Hu HH, Liu J, Lin YL, Luo WS, Chu YJ, Chang CL, Jen CL, Lee MH, **Lu SN**, Wang LY, You SL, Yang HI, Chen CJ; REVEAL-HBV Study Group. The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B. *Gut.* 2016 Sep;65(9):1514-21.(SCI)
336. Wang JH, Chen TY(co-first), Ou HY, Wang CC, Liu YW, Hung CH, Chen CH, Kuo CH, Hu TH, Cheng YF, **Lu SN\***. Clinical Impact of Gadoteric Acid-Enhanced Magnetic Resonance Imaging on Hepatoma Management: A Prospective Study. *Dig Dis Sci.* 2016 Apr;61(4):1197-205. (SCI)
337. Hung CH\*, Hu TH, **Lu SN**, Chen CH, Wang JH, Lee CM. Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C. *J Formos Med Assoc.* 2016 Apr;115(4):278-83. (SCI)
338. Wang HM, Hung CH, Lee CM, **Lu SN**, Wang JH, Yen YH, Kee KM, Chang KC, Tseng PL, Hu TH\*, Chen CH\*. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and -experienced chronic hepatitis B patients. *J Gastroenterol Hepatol.* 2016 Jul;31(7):1307-14. (SCI)
339. Lee CM, Hu TH, **Lu SN**, Wang JH, Hung CH, Chen CH, Yen YH\*. Suppressor of cytokine signaling 1 expression in peripheral blood mononuclear cells of hepatitis C genotype 1 patients. *J Formos Med Assoc.* 2016 Jun;115(6):440-4. (SCI)
340. Liu J, Yang HI, Lee MH, Jen CL, Hu HH, **Lu SN**, Wang LY, You SL, Huang YT, Chen CJ. Alcohol Drinking Mediates the Association between Polymorphisms of ADH1B and ALDH2 and Hepatitis B-Related Hepatocellular Carcinoma. *Cancer Epidemiol Biomarkers Prev.* 2016 Apr;25(4):693-9. (SCI)
341. Wu CK, Chang KC, Tseng PL, **Lu SN**, Chen CH, Wang JH, Lee CM, Lin MT, Yen YH, Hung CH, Hu TH\*. Comparison of Therapeutic Response and Clinical Outcome between HCV Patients with Normal and Abnormal Alanine Transaminase Levels. *PLoS One.* 2016 Mar 11;11(3):e0142378. (SCI)

342. Lu SY, Tsai CY, Lin LH, **Lu SN**. Dental extraction without stopping single or dual antiplatelet therapy: results of a retrospective cohort study. *Int J Oral Maxillofac Surg*. 2016 Oct;45(10):1293-8. (SCI)
343. Yeh JH, Hung CH, Wang JH, Kuo YH, Tai WC, **Lu SN**\*. Hepatocellular carcinoma detected by regular surveillance: Does timely confirmation of diagnosis matter? *Dig Liver Dis*. 2016 Jun;48(6):661-6. (SCI)
344. Wu CK, Chang KC, Hung CH, Tseng PL, **Lu SN**, Chen CH, Wang JH, Lee CM, Tsai MC, Lin MT, Yen YH, Hu TH\*. Dynamic  $\alpha$ -fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy. *J Antimicrob Chemother*. 2016 Jul;71(7):1943-7. (SCI)
345. Liu J, Yang HI, Lee MH, Jen CL, Batrla-Utermann R, **Lu SN**, Wang LY, You SL, Chen CJ\*. Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression. *Hepatology*. 2016 Aug;64(2):381-9. (SCI)
346. Chien J\*, Liu J, Lee MH, Jen CL, Batrla-Utermann R, **Lu SN**, Wang LY, You SL, Yang HI, Chen CJ. Risk and Predictors of Hepatocellular Carcinoma for Chronic Hepatitis b Patients With Newly Developed Cirrhosis. *J Gastroenterol Hepatol*. 2016 Dec;31(12):1971-1977. (SCI)
347. Kuo YH, Tsai MC, Kee KM, Chang KC, Wang JH, Lin CY, Lin SC, **Lu SN**\*. Associated Factors for Metabolic Syndrome in the Older Adults with Chronic Virus Hepatitis in the Community. *PLoS One*. 2016 May 13;11(5):e0155544. (SCI)
348. Yong CC, Tsai MC, Lin CC\*, Wang CC, **Lu SN**, Hung CH, Hu TH, Chen CL. Comparison of Salvage Living Donor Liver Transplantation and Local Regional Therapy for Recurrent Hepatocellular Carcinoma. 2016 Oct;40(10):2472-80. (SCI)
349. Wang JH, Yen YH, Yao CC, Hung CH, Chen CH, Hu TH, Lee CM, **Lu SN**\*. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful anti-viral therapy. *Liver Int*. 2016 Dec;36(12):1793-1799. (SCI)
350. Kee KM, Wang JH, Wang CC, Cheng YF, **Lu SN**\*. Hepatocellular Carcinoma associated with Extra-hepatic Primary Malignancy: its Secular change, Clinical Manifestations and Survival. *Sci Rep*. 2016 Jul 22;6:30156. (SCI)
351. Lee CM, Hu TH, **Lu SN**, Wang JH, Hung CH, Chen CH, Yen YH\*. Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients. *BMC Gastroenterol*. 2016 Jul 25;16(1):73. (SCI)
352. Ali MA, Li WF, Wang JH, Lin CC, Chen YJ, Lin TL, Lin TS, **Lu SN**, Wang CC\*, Chen CL. Impact of pathological features of primary hepatocellular carcinoma on the outcomes of intrahepatic recurrence management: single center experience from Southern Taiwan. *HPB (Oxford)*. 2016 Oct;18(10):851-860. (SCI)
353. Foster GR, Chayama K, Chuang WL, Fainboim H, Farkkila M, Gadano A, Gaeta GB, Hézode C, Inada Y, Heo J, Kumada H, **Lu SN**, Marcellin P, Moreno C, Roberts SK, Strasser SI, Thompson AJ, Toyota J, Paik SW, Vierling JM, Zignego AL, Cohen D, McPhee F, Wind-Rotolo M, Srinivasan S\*, Hruska M, Myler H, Portsmouth SD. A randomized, controlled study of peginterferon lambda-1a/ribavirin  $\pm$  daclatasvir for hepatitis C virus genotype 2 or 3. *Springerplus*. 2016 Aug 19;5(1):1365. (SCI)
354. Yen YH, Huang CM, Wei KL, Wang JH, **Lu SN**, Lee CM, Hung CH, Chen CH, Tseng PL, Chang KC, Tsai MC, Lin MT, Wu CK, Yang CH, Moi SH, Cho CL, Hu TH\*. MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin. *Sci Rep*. 2016 Sep 26;6:33816. (SCI)
355. Lin SM\*, **Lu SN**, Chen PT, Jeng LB, Chen SC, Hu CT, Yang SS, Le Berre MA, Liu X, Mitchell DY, Prins K, Grevel J, Peña CA, Meinhardt G. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. *Hepatol Int*. 2017 Mar;11(2):199-208. (SCI)
356. Chien TL, Wang JH, Kee KM, Chen CH, Hung CH, **Lu SN**\*. Factors Predicting HBsAg Seroclearance and Alanine Transaminase Elevation in HBeAg-Negative Hepatitis B Virus-Infected Patients with Persistently Normal Liver Function. *PLoS One*. 2016 Dec 9;11(12):e0166543. (SCI)
357. Hung CH, Wang JH, **Lu SN**, Hu TH, Lee CM, Chen CH\*. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy. *J Viral Hepat*. 2017 Jul;24(7):599-607. (SCI)
358. Huang CF, Yeh ML, Huang CI, Lin YJ, Tsai PC, Lin ZY, Chan SY, Chen SC, Yang HI, Huang JF, **Lu SN**, Dai CY, Jen CL, Yuan Y, L'Italien G, Wang LY, Lee MH\*, Yu ML\*, Chuang WL, Chen CJ. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. *Oncotarget*. 2017 Jul 4;8(27):43925-43933. (SCI)
359. Lin YJ, Shaw TG, Yang HI, **Lu SN**, Jen CL, Wang LY, Wong KH, Chan SY, Yuan Y, L'Italien G, Chen CJ, Lee MH\*, R.E.V.E.A.L.-HCV Study Group. Chronic hepatitis C virus infection and the risk for diabetes: a community-based prospective study. *Liver Int*. 2017 Feb;37(2):179-186. (SCI)

360. Kee KM, **Lu SN\***. Diagnostic efficacy of ultrasound in hepatocellular carcinoma diagnosis. *Expert Rev Gastroenterol Hepatol*. 2017 Apr;11(4):277-279. (SCI)
361. Wu IT, Hu TH, Hung CH, **Lu SN**, Wang JH, Lee CM, Chen CH\*. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naïve chronic hepatitis B patients with high viraemia: a retrospective cohort study. *Clin Microbiol Infect*. 2017 Jul;23(7):464-469. . (SCI)
362. Kuo YH, Wang JH, Hung CH, Rau KM, Wu IP, Chen CH, Kee KM, Hu TH, **Lu SN\***. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. *J Gastroenterol Hepatol*. 2017 Dec;32(12):1975-1981(SCI)
363. Espinosa W, Liu YW, Wang CC, Lin CC, Wang JH, **Lu SN**, Hung CH. Combined resection and radiofrequency ablation versus transarterial embolization for intermediate-stage hepatocellular carcinoma: A propensity score matching study. *J Formos Med Assoc*. 2018 Mar;117(3):197-203. (SCI)
364. Wu CH, Hsu TY, Kung FT, ChangChien CC, Tsai CC, **Lu SN\***. Changes in the Prevalence of HBsAg and HBeAg: a Study of 8696 Parturients in a Well Vaccinated Area. *Sci Rep*. 2017 Apr 27;7(1):1212. (SCI)
365. Kuo YH, Wu IP, Wang JH, Hung CH, Rau KM, Chen CH, Kee KM, Hu TH, **Lu SN\***. The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis. *Invest New Drugs*. 2018 Apr;36(2):307-314.
366. Yao CC, Hung CH, Hu TH, **Lu SN**, Wang JH, Lee CM, Chen CH\*. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg $\leq$ 200IU/mL. *Sci Rep*. 2017 May 12;7(1):1839. (SCI)
367. Chu YJ, Yang HI, Wu HC, Liu J, Wang LY, **Lu SN**, Lee MH, Jen CL, You SL, Santella RM, Chen CJ. Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers. *Int J Cancer*. 2017 Aug 15;141(4):711-720. (SCI)
368. Lai TS, Lee MH, Yang HI, You SL, **Lu SN**, Wang LY, Yuan Y, L'Italien G, Chien KL, Chen CJ; REVEAL-HCV Study Group. Hepatitis C Viral Load, Genotype, and Increased Risk of Developing End-stage Renal Disease: REVEAL-HCV Study. *Hepatology*. 2017 Sep;66(3):784-793. (SCI)
369. Lee MH#\*, Huang CF, Lai HC, Lin CY, Dai CY, Liu CJ, Wang JH, Huang JF, Su WP, Yang HC, Kee KM, Yeh ML, Chuang PH, Hsu SJ, Huang CI, Kao JT, Chen CC, Chen SH, Jeng WJ, Yang HI, Yuan Y, **Lu SN#**, Sheen IS#, Liu CH#, Peng CY#, Kao JH#, Yu ML#, Chuang WL#, Chen CJ#. Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. *Sci Rep*. 2017 Jun 16;7(1):3718. (# co-first)
370. Hung CH\*, Kee KM, Chen CH, Tseng PL, Tsai MC, Chen CH, Wang JH, Chang KC, Kuo YH, Yen YH, Hu TH, **Lu SN**. A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute Exacerbation. *Clin Transl Gastroenterol*. 2017 Jun 29;8(6):e104. (SCI)
371. Tsai MC, Chen CH, Hu TH, **Lu SN**, Lee CM, Wang JH, Hung CH\*. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. *J Formos Med Assoc*. 2017 July; 116(7)512-521. (SCI)
372. Huang CM, Chang KC, Hung CH, Chiu KW, **Lu SN**, Wang JH, Chen CH, Kee KM, Kuo YH, Tsai MC, Tseng PL, Lin MT, Wu CK, Hu TH, Cho CL, Yen YH\*. Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C. *PLoS One*. 2017 Aug 10;12(8):e0182204. (SCI)
373. Lee MH, Huang YH, Chen HY, Khor CS, Chang YH, Lin YJ, Jen CL, **Lu SN**, Yang HI, Nishida N, Sugiyama M, Mizokami M, Yuan Y, L'Italien G, Tokunaga K, Chen CJ; REVEAL-HCV cohort. Human Leukocyte Antigen Variants and Risk of Hepatocellular Carcinoma Modified by HCV Genotypes: A Genome-wide Association Study. *Hepatology*. 2017 Sep 16. doi: 10.1002/hep.29531. [Epub ahead of print]
374. Lai TS, Lee MH, Yang HI, You SL, **Lu SN**, Wang LY, Yuan Y, L'Italien G, Chien KL, Chen CJ; REVEAL-HCV Study Group. High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease. *Kidney Int*. 2017 Sep;92(3):703-709.
375. Liu J, Hu HH, Lee MH, Korenaga M, Jen CL, Batrla-Utermann R, **Lu SN**, Wang LY, Mizokami M, Chen CJ, Yang HI. Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients. *Sci Rep*. 2017 Oct 30;7(1):14352
376. Yen YH, Tsai MC, Wu CK, Chang KC, Hung CH, Chiu KW, **Lu SN**, Wang JH, Chen CH, Kee KM, Kuo YH, Tseng PL, Lin MT, Huang CM, Lin JT, Hu TH. Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study. *J Formos Med Assoc*. 2018 Sep;117(9):833-840.
377. Huang CM, Hu TH, Chang KC, Tseng PL, **Lu SN**, Chen CH, Wang JH, Lee CM, Tsai MC, Lin MT, Yen YH, Hung CH, Cho CL, Wu CK. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents. *Medicine (Baltimore)*. 2017 Nov;96(46):e8696.
378. Yen YH, Lin MT, Kuo FY, Chang KC, Tsai MC, Tseng PL, Wu CK, Lin JT, Hu TH, **Lu SN**, Wang JH, Hung

- CH, Chen CH. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients. *Liver Int.* 2018 Jun;38(6):1064-1073.
379. Chu YJ, Yang HI, Wu HC, Lee MH, Liu J, Wang LY, **Lu SN**, Jen CL, You SL, Santella RM, Chen CJ. Aflatoxin B<sub>1</sub> exposure increases the risk of hepatocellular carcinoma associated with hepatitis C virus infection or alcohol consumption. *Eur J Cancer.* 2018 May;94:37-46.
380. Kuo MT, Tseng PL, Chou YP, Chang KC, Tsai MC, Kuo YH, Hu TH, Hung CH, Wang JH, **Lu SN**, Chen CH. Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy. *J Gastroenterol Hepatol.* 2018 Mar 7. doi: 10.1111/jgh.14142.
381. Chen CH, Hung CH, Wang JH, **Lu SN**, Hu TH, Lee CM. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. *Clin Microbiol Infect.* 2017 Dec 26. pii: S1198-743X(17)30688-2. doi: 10.1016/j.cmi.2017.12.013.
382. Chen CH, Hsu YC, **Lu SN**, Hung CH, Wang JH, Lee CM, Hu TH. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients. *J Viral Hepat.* 2018 May;25(5):590-597..
383. Chen CH, Lee CM, Lai HC, Hu TH, Su WP, **Lu SN**, Lin CH, Hung CH, Wang JH, Lee MH, Peng CY. Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir. *Oncotarget.* 2017 Sep 28;8(54):92431-92441.
384. Chiang HH, Lee CM, Hu TH, Hung CH, Wang JH, **Lu SN**, Lai HC, Su WP, Lin CH, Peng CY, Chen CH. A combination of the on-treatment FIB-4 and alpha-fetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir. *Liver Int.* 2018 May 24. doi: 10.1111/liv.13889.
385. Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH, **Lu SN**, Wang JH, Hung CH, Chen CH. APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level. *PLoS One.* 2018 Jun 28;13(6):e0199760. doi: 10.1371/journal.pone.0199760. eCollection 2018.
386. Wang HW, Lai HC, Hu TH, Su WP, **Lu SN**, Lin CH, Hung CH, Chuang PH, Wang JH, Lee MH, Chen CH, Peng CY. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy. *J Gastroenterol Hepatol.* 2018 Jul 3. doi: 10.1111/jgh.14372.
387. Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH, **Lu SN**, Wang JH, Hung CH, Chen CH. Diabetes is associated with advanced fibrosis and fibrosis progression in non-genotype 3 chronic hepatitis C patients. *Dig Liver Dis.* 2018 Jul 17. pii: S1590-8658(18)30814-4. doi: 10.1016/j.dld.2018.07.003.
388. Kuo YH, Kee KM, Wang JH, Hsu NT, Hsiao CC, Chen Y, **Lu SN\***. Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population-based study. *Aliment Pharmacol Ther.* 2018 Sep 11. doi: 10.1111/apt.14960.
389. Liu J, Hu HH, Chang CL, Jen CL, Lee MH, **Lu SN**, Wang LY, Yuan Q, Xia NS, Sugiyama M, Nishida N, Mizokami M, Chen CJ, Chen PJ, Yang HI. Association Between High Levels of Hepatitis B Core Antibody and Seroclearance of HBeAg in Individuals With Chronic HBV Infection. *Clin Gastroenterol Hepatol.* 2018 Sep 26. pii: S1542-3565(18)31028-0.
390. Lin YJ, Chang CL, Chen LC, Hu HH, Liu J, Korenaga M, Huang YH, Jen CL, Su CY, Nishida N, Sugiyama M, **Lu SN**, Wang LY, Yuan Y, L'Italien G, Yang HI, Mizokami M, Chen CJ, Lee MH. A Glycomarker for Short-term Prediction of Hepatocellular Carcinoma: A Longitudinal Study With Serial Measurements. *Clin Transl Gastroenterol.* 2018 Sep 20;9(9):183.
391. Chang WT, **Lu SN**, Rau KM, Huang CS, Lee KT. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients. *Kaohsiung J Med Sci.* 2018 Jul;34(7):391-399.
392. Hu HH, Liu J, Chang CL, Jen CL, Lee MH, **Lu SN**, Wang LY, Quan Y, Xia NS, Chen CJ, Chen PJ, Yang HI. Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients. *Clin Gastroenterol Hepatol.* 2018 May 9. pii: S1542-3565(18)30472-5.
393. Yen CW, Kuo YH, Wang JH, Chang KC, Kee KM, Hung SF, Chen Y, Tsai LS, Chen SC, Hung CH, **Lu SN\***. Did AFP-L3 save ultrasonography in community screening? *Kaohsiung J Med Sci.* 2018 Oct;34(10):583-587.
394. Kuo YH, **Lu SN**. Editorial: hepatitis B, fatty liver and metabolic syndrome-Interaction or co-existence? Authors' reply. *Aliment Pharmacol Ther.* 2018 Nov;48(10):1162-1163.
395. Chu MO, Shen CH, Chang TS, Xu HW, Yen CW, **Lu SN**, Hung CH. Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation. *Sci Rep.* 2018 Nov 9;8(1):16611. Kuo MT, Hu TH, Hung CH, Wang JH, **Lu SN**, Tsai KL, Chen CH. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. *Aliment Pharmacol Ther.* 2019 Jan;49(2):218-228.
396. Chang C, Hung CH, Wang JH, **Lu SN\***. Hepatitis C core antigen highly correlated to HCV RNA. *Kaohsiung J Med Sci.* 2018 Dec;34(12):684-688.
397. Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, **Lu SN**, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. *J Formos Med Assoc.* 2019 Jan;118(1 Pt 1):7-38.

398. Sou FM, Wu CK, Chang KC, **Lu SN**, Wang JH, Hung CH, Chen CH, Kee KM, Yen YH, Lin MT, Tsai MC, Hu TH. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders. *J Formos Med Assoc.* 2019 Jan;118(1 Pt 3):504-513.
399. Yen YH, Kee KM, Kuo FY, Chang KC, Hu TH, **Lu SN**, Wang JH, Hung CH, Chen CH. A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfecting patients treated with interferon and ribavirin in an Asian cohort. *Medicine (Baltimore).* 2018 Dec;97(50):e13383.
400. Kuo YH, **Lu SN**\*. Letter: the association between chronic viral hepatitis and metabolic syndrome - Authors' reply. *Aliment Pharmacol Ther.* 2019 Jan;49(2):233-234.
401. Yen YH, Kee KM, Chen CH, Hu TH, **Lu SN**, Wang JH, Hung CH. Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C. *PLoS One.* 2019 Jan 9;14(1): e0208858.
402. Chen CH, Hung CH, Wang JH, **Lu SN**, Lai HC, Hu TH, Lin CH, Peng CY. The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy. *J Infect Dis.* 2019 Apr 19;219(10):1624-1633.
403. Chen YH, **Lu SN**, Wang JH, Hung CH, Hu TH, Chen CH. Pre-S/Surface and Core Promoter/Precore Mutations in Chronic Hepatitis B Patients with Severe Acute Exacerbation. *Dig Dis Sci.* 2019 Mar 5.
404. Huang YN, Lu YB, **Lu SN**\*. Sequential bilateral PVTT successfully controlled by radiotherapy and sorafenib, respectively. *Kaohsiung J Med Sci.* 2019 Jan;35(1):63-64.
405. Lee YC, Hu TH, Hung CH, **Lu SN**, Chen CH, Wang JH. The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals. *PLoS One.* 2019 Apr 2;14(4):e0214323.
406. Chen CH, Chen CH, Lin CL, Lin CY, Hu TH, Tung SY, Hsieh SY, **Lu SN**, Chien RN, Hung CH, Sheen IS. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. *Sci Rep.* 2019 May 8;9(1):7086.

Signature: 盧勝男 Sheng-Nan Lu

Date: 12/May/2019